ABCD
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Protocol for non -interventional studies based on existing data
TITLE PAGE
Document Number: c30445781 -01
BI Study Number: 1237-0090
BI Investigational
Product(s):Stiolto ®Respimat®
Title:The Role of Inhaler Device i n the Treatment Persistence with Dual 
Bronchodilators in Patients w ith COPD
Protocol version 
identifier:1.0
Date of last version of 
protocol:N/A
PASS: No
EU PAS register 
number:Study not registered
Active substance:Olodaterol and Tiotropium Bromide (ATC R03AL06)
Umeclidinium and Vilanterol (ATC R03AL03)
Medicinal product: Stiolto® Respimat®; Anoro® Ellipta®
Product reference: N/A
Procedure number: N/A
Joint PASS: No
Research question and 
objectives:The primary objective of the study is to use US data to determine 
relative persistence between Olodaterol/ Tiotropium Bromide 
delivered with the Respimat softmist inhaler and
Umeclid inium/ Vilanterol delivered with the Ellipta dry powder
inhaler using a 1:2 propensity score matched analysis.
The secondary objectives of the study are as follows:
-Characterize new users of Olodaterol/Tiotropium Bromide 
and Umeclidinium/Vilanterol in terms of demographics, 
medication use, comorbidities, and other variables , before 
and after propensity score matching.
-Determine the incidence rate 
and proportion of patients 
discontinuing or switching among new users of 
Olodaterol/Tiotropium Bromide and Umeclidinium/
Vilanterol .
-Determine the relative rate and proportion of patients 
discontinuing between Olodaterol/ Tiotropium Bromide and
Boehringer Ingelheim Page 2of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companie s
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Umeclidinium/Vilanterol. using a standard multivariate 
analysis (If feasible).
Country( -ies) of study: United States
Author:T: 
Email:
T:
Email: 
BI contact person: 
Marketing 
authorisation 
holder(s):
MAH contact person:
In case of PASS, add: N/A
In case of PASS, add: N/A
Date: 22November 2019
Page 1 of 69
Proprietary confidential information
© 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not -in full or in part -be passed on, reproduced, published or otherwise used without prior written permission

Boehringer Ingelheim Page 3of 69
Protocol for non-interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companie s
001-MCG-102_RD -02(1.0) /Saved on:22Oct20151. TABLE OF CONTENTS
TITLE PAGE ............................................................................................................................. 1
1. TABLE OF CONTENTS ............................................................................................... 3
2.
LIST OF ABBREVIATIONS........................................................................................ 5
3. RESPONSIBLE PARTIES ............................................................................................ 6
4. ABSTRACT ................................................................................................................... 7
5. AMENDMENTS AND UPDATES ............................................................................. 15
6. MILESTONES ............................................................................................................. 15
7. RATIONALE AND BACKGROUND ........................................................................ 15
8. RESEARCH QUESTI ON AND OBJECTI VES .......................................................... 16
9.
RESEARCH METHODS ............................................................................................ 17
9.1 STUDY DESIGN ................................ ................................ .......................... 17
9.2 SETTI NG................................ ................................ ................................ ......17
9.2.1 Definitions..................................................................................................... 17
9.2.2 Study  population ............................................................................................ 19
9.3 VARIABLES ................................................................................................. 20
9.3.1 Exposures ................................ ................................ ................................ ......20
9.3.2 Outcomes ................................ ................................ ................................ .......20
9.3.2.1 Primary  outcome ................................ ................................ .......................... 20
9.3.2.2 Secondary  outcomes ................................ ................................ .................... 21
9.3.3 Covariates ................................ ................................ ................................ ......21
9.4 DATA SOURCES ................................ ................................ ......................... 23
9.5 STUDY SIZE ................................ ................................ ................................ 23
9.6 DATA MANAGEMENT ................................ ................................ .............. 23
9.7 DATA ANALYSI S ....................................................................................... 24
9.7.1 Main anal ysis................................ ................................ ................................ .24
9.7.1.1 Descriptive Analy sis.................................................................................... 24
9.7.1.2
Rates and Risks................................ ................................ ............................ 24
9.7.1.3 Comparative Persistence ................................ ................................ .............. 25
9.7.2 Sensitivity  Anal ysis................................ ................................ ....................... 26
9.8 QUALITY CONTROL ................................ ................................ ................. 27
9.9 LIMITATIONS OF THE RESEARCH METHODS .................................... 28
Boehringer Ingelheim Page 4of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct20159.10 OTHER ASPECTS ................................ ................................ ........................ 28
9.11 SUBJECTS .................................................................................................... 28
9.11.1 Cases .............................................................................................................. 28
9.11.2 Controls ......................................................................................................... 29
9.12 BIAS .............................................................................................................. 29
10. PROTECTI ON OF HUMAN SUBJECTS .................................................................. 29
11. MANAGEMENT AND REPORTI NG OF ADVERSE EVENTS/ADVERSE 
REACTI ONS ............................................................................................................... 30
12. PLANS FOR DI SSEMINATING AND COMMUNI CATING STUDY RESUL TS..30
13. REFERENCES ............................................................................................................. 31
13.1 PUBLISHED REFERENCES ....................................................................... 31
13.2 UNPUBLISHED REFERENCES ................................................................. 32
ANNEX 1. LIST OF STAND
-ALONE DOCUMENTS ......................................................... 33
ANNEX 2. ENCEPP CHECKLIST FOR STUDY PROTOCOL S
......................................... 34
ANNEX 3: LIST OF MEDI CATION MEASURE DEFINITIONS ........................................ 35
ANNEX 4. LIST OF COMORBIDITY, SYMPTOMS AND OTHER MEASURE 
DEFIN IT
IONS............................................................................................................. 38
ANNEX 5. TABLE SHELLS AND PROPOSED FIGURES ................................................. 60
Boehringer Ingelheim Page 5of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct20152. LIST OF ABBREVIATION S
ACE Angiotensin Converting Enzy me
AIDS Acquired Immune Deficiency  Syndrome
CCAE Commercial Claims and Encounters
CDCI Charlson Dey oComorbidity  Index
CI Confidence Interval
COB Coordination of Benefits
COBRA Consolidated Omnibus Budget Reconciliation Act
COPD Chronic Obstructive Pulmonary  Disease
CT Computed Tomograph y
DPI Dry Powder Inhaler
ENCEPP European Network of Centres for Pharmacoepidemiology  and Pharmacovigilance
ESRD End Stage Renal Disease
FDC Fixed Dose Combination
GLP
-1 Glucagon -like Peptide -1
GOLD Global I nitiative for Chronic Obstructive Lung Disease
HIV Human Immunodeficiency  Virus
ICD International Classification of Diseases
ICS Inhaled Corticosteroid
IP Inpatient
IQR Interquartile Range
IRB Institutional Review Board
LABA
LAMALong -Acting Beta-Agonists
Long -Acting Muscarinic Antagonists
NDC National Drug Code
NSAID Nonsteroidal Anti -inflammatory  Drug
OCS Oral Corticosteroid
OP Outpatient
SABA Short -acting Beta Agonist
SAMA Short -acting Muscarinic Antagonist
SD Standard Deviation
SMI Soft Mist Inhaler
Boehringer Ingelheim Page 6of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct20153. RESPONSIBLE PARTIES
T: 
Email: 
Email:
T: 
Email: 
T: 
Email: 

Boehringer Ingelheim Page 7of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct20154. ABSTRACT
Name of company:
Boehringer Inge lheim International 
GmbH
Name of finished medicinal product:
Stiolto® Respimat®; Anoro® Ellipta®
Name of active ingredient:
Olodaterol and Tiotropium Bromide 
(ATC R03AL06) ;Umeclidinium and 
Vilanterol (ATC R03AL03)
Protocol date: Study number: Version/Revision:Version/Revision 
date:
22November 2019 1237-00 90 1.0 NA
Title of study:The Role of Inhaler sIn Treatment Persistence With Dual 
Bronchodilators In Patients With COPD
Rationale and 
backgroundInhaled therapies are the cornerstone of chronic obstructive lung disease 
(COPD) management approaches. The aim of inhaled therapy is to deliver 
therapeutic agents directly to the lungs, optimizing benefits while
minimizing the potential for treatment -related adverse effects (Braido 
2016) .
Adherence to COPD therapies involves patients initiating their prescribed 
therapy, implementing it as prescribed (i.e., correctly administering the 
prescribed dose at the physician directed frequency), and persisting with 
treatment (Braido 2016; Mäkelä 2013) . Also central to the therapeutic 
benefit of inhaled therapies is their successful administration, which 
requires patients to have knowledge and understanding of (and ability to 
implement) the appropriate inhaler technique required to optimize both the 
dispensed and admi nistered doses (Braido 2016) . Inspiratory capabilities 
of patients with COPD are affected by increasing static and dynamic 
hyperinflation and weakening of the respiratory muscles, causing many 
patients to have peak inspiratory flow rates that are suboptimal to use many 
dry-powder inhalers (DPIs) (Sohini 2017) . This paradoxical situation may 
lead to improper inhalation that prevents successful drug delivery to the 
lungs, which may affect treatment efficacy. The question ifdifferent 
devices , DPI and Soft Mist Inhalers ( SMI) ,playeda role in treatment 
persistence remains to be answered. 
In this study we aim to compare the persistence in using two 
different 
medications from the same drug class (LAMA/LABA FDC) which are 
delivered through different devices, a DPI and a nSMI.
Boehringer Ingelheim Page 8of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Name of company:
Boehringer Inge lheim International 
GmbH
Name of finished medicinal product:
Stiolto® Respimat®; Anoro® Ellipta®
Name of active ingredient:
Olodaterol and Tiotropium Bromide 
(ATC R03AL06) ;Umeclidinium and 
Vilanterol (ATC R03AL03)
Protocol date: Study number: Version/Revision:Version/Revision 
date:
22November 2019 1237-00 90 1.0 NA
Research question 
and objectives:This study seeks to compare the differences in treatment persistence in 
using two combinations of two drugs of the same drug class 
(LAMA/LABA as a fixed dose combination) delivered through different 
devices (a DPI or an SMI) within an administrative claims database in the 
US.
The primary  objective of the study  is to use US data to determine 
relative treatment persiste nce between patients prescribed
Olodaterol/Tiotropium Bromide delivered with the Respimat SMI
and Umeclidinium/Vilanterol delivered with the Ellipta DPIusing a 
1:2 propensity  score matched analy sis.
The secondary objectives of the study are as follows:
-Characterize new users of Olodaterol/Tiotropium Bromide and
Umeclidinium/Vilanterol in terms of demographics, medication 
use, comorbidities, and other variables, before and after propensity 
score matching.
-Determine the rate and risk 
(proportion of patient s) of 
discontinuation among new users of Olodaterol/Tiotropium
Bromide and Umeclidinium/ Vilanterol in the 1:2 matched cohort .
-Determine the relative rate and risk of discontinuation between 
Olodaterol/ Tiotropium Bromide and Umeclidinium/Vilanterol ,
using a standard multivariable analysis (Same variables as 
propensity score model )in the total unmatched cohort .
Study design:New-user cohort design with propensity scores used to match up to 2
Umeclidinium/Vilanterol initiator s to each Olodaterol/Tiotropium Bromide
initiator .
Population:Patients initiating Olodaterol/Tiotropium Bromide or Umeclidinium /
Vilanterol between 17 November 2015 and 31March 2018.
Exclusion criteria are:
Aged <40 years .
Enrolment with medical and pharmacy coverage prior to the cohort 
entry < 180 days.
Never had COPD diagnosis on the cohort entry date or prior to 
cohort entry.
Boehringer Ingelheim Page 9of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Name of company:
Boehringer Inge lheim International 
GmbH
Name of finished medicinal product:
Stiolto® Respimat®; Anoro® Ellipta®
Name of active ingredient:
Olodaterol and Tiotropium Bromide 
(ATC R03AL06) ;Umeclidinium and 
Vilanterol (ATC R03AL03)
Protocol date: Study number: Version/Revision:Version/Revision 
date:
22November 2019 1237-00 90 1.0 NA
A record for dispensed Olodaterol/Tiotropium Bromide delivered 
with Respimat inhalator or Umeclidinium/Vilanterol delivered with 
the Ellipta Inhaler during the 180- day baseline prior to cohort 
entry .
Diagnosis of a sthma any time prior to cohort entry.
Diagnosis of lung cancer any time prior to cohort entry .
Diagnosis of lung transplant any time prior to cohort entry.
Boehringer Ingelheim Page 10of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Name of company:
Boehringer Inge lheim International 
GmbH
Name of finished medicinal product:
Stiolto® Respimat®; Anoro® Ellipta®
Name of active ingredient:
Olodaterol and Tiotropium Bromide 
(ATC R03AL06) ;Umeclidinium and 
Vilanterol (ATC R03AL03)
Protocol date: Study number: Version/Revision:Version/Revision 
date:
22November 2019 1237-00 90 1.0 NA
Variables:Exposures
Olodaterol/Tiotropium Bromide (Stiolto®) delivered via Respimat 
inhaler 
Umeclidinium/Vilanterol (Anoro®) delivered via Ellipta Inhaler
Outcome
Discontinuation of index treatment (Olodaterol/Tiotropium 
Bromide orUmeclidinium/Vilanterol ), defined as persistence of 
treatment ( no refill claim within 60 days (allowable grace period) 
after end o f <n> days supply ).Addition of another drug will not 
count as a discontinuation.
Covariates
Demographics
●Age on the cohort entry date
● Sex (Male, Female)
●Region (Northeast, North Central, South, West, Unknown, 
Missing )
●Insurance Type (Commercial, Medicare, Missing)
●Study Year of Cohort Entry (First Y ear: 17Nov 2015-30 Nov
2016, Second Year: 01Dec2016- 30 Nov 2017, Third Year: 01 
Dec 2017 -31 Mar 2018 )
Concomita nt Medications
●Oral Corticosteroids (OCS)
●Short acting muscarinic antagonist (SAMA)
●Short acting beta agonist (SABA)
●Long acting muscarinic antagonist (LAMA)
●Long acting beta agonist (LABA)
●Inhaled corticosteroid (ICS)
●LAMA / LABA combination (that is not Stiolto or Anoro)
●LABA / ICS combination
●LAMA / LABA / ICS combination
●NSAIDs
●Antihistamines
Boehringer Ingelheim Page 11of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Name of company:
Boehringer Inge lheim International 
GmbH
Name of finished medicinal product:
Stiolto® Respimat®; Anoro® Ellipta®
Name of active ingredient:
Olodaterol and Tiotropium Bromide 
(ATC R03AL06) ;Umeclidinium and 
Vilanterol (ATC R03AL03)
Protocol date: Study number: Version/Revision:Version/Revision 
date:
22November 2019 1237-00 90 1.0 NA
●Opioids
●Oral antibiotics
●Antidiabetic Agents (not including insulin)
●Insulin (basal or mealtime)
●Methotrexate
●Statins
●Antihypertensives
●Anticoagulants
● Anti- psychotic/anti -depressives/anxiolytic
●Oxygen therapy
Comorbidities /Symptoms
●History of All -Cause Hospitalization
●History of Emergency Department Visit
●History of Hospitalization due to Respiratory Condition
●Acute Myocardial Infarction
●Angina Pectori s
●Peripheral Vascular Disease
●Heart Failure
●Hypertension
●Upper Respiratory Infection
●Lower Respiratory Infection
●Cardiac Arrhythmias
●Cerebrovascular Disease
●All cancers (except non- melanoma skin cancer )
●Allergic Rhinitis
●Chronic Sinusitis
●Bronchiectasis
●Pneumonia
●Chronic Bronchitis
●Exertional Breathlessness
●Anxiety
●Dementia
●Depression
●Osteoporosis
●Charlson- Deyo Comorbidity Index 
Boehringer Ingelheim Page 12of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Name of company:
Boehringer Inge lheim International 
GmbH
Name of finished medicinal product:
Stiolto® Respimat®; Anoro® Ellipta®
Name of active ingredient:
Olodaterol and Tiotropium Bromide 
(ATC R03AL06) ;Umeclidinium and 
Vilanterol (ATC R03AL03)
Protocol date: Study number: Version/Revision:Version/Revision 
date:
22November 2019 1237-00 90 1.0 NA
●Acute Liver Injury or Failure
●Chronic Kidney Disease (without ESRD)
●End Stage Renal Disease
●Rheumatic Disease
●Peptic Ulcer Dise ase
●Gastroesophageal Reflux Disease
●Type 1 Diabetes Mellitus
●Type 2 Diabetes Mellitus
●HIV/AIDS
●Hemiplegia or Paraplegia
Lifestyle
●Smoking -related claim
●Vaccination for Influenza
●Vaccination for Pneumococcus
Respiratory Function Procedures/Tests Conducted
●Pulmonary function tests
●Six-minutewalk test
●Chest X -ray
●High resolution chest CT
Boehringer Ingelheim Page 13of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Name of company:
Boehringer Inge lheim International 
GmbH
Name of finished medicinal product:
Stiolto® Respimat®; Anoro® Ellipta®
Name of active ingredient:
Olodaterol and Tiotropium Bromide 
(ATC R03AL06) ;Umeclidinium and 
Vilanterol (ATC R03AL03)
Protocol date: Study number: Version/Revision:Version/Revision 
date:
22November 2019 1237-00 90 1.0 NA
Data sources:Truven MarketScan is a claims database that captures longitudinal, 
individual -level administrative claims data from the United States. 
Study size:There are14,751 new users of Olodaterol/Tiotropium Bromide or 
Umeclidinium/Vilanterol between 17 November 2015 and 31 March 2018
who satisfied the inclusion criteria . Among them, 3,889 initiated 
Olodaterol/Tiotropium Bromide and 10,862 initiated Umeclidinium/
Vilanterol) .
Data analysis:For demographic and lifestyle variables, the value recorded on the cohort 
entry date will be reported, otherwise the most recent known value will be 
reported. Presence of comorbidities and use of concomitant medication use 
willbe determined based whether they ever occurred within the 180 -day 
baseline p eriod preceding the index date. Differences in the confounder 
distributions will be inspected for successful confounder balance of 
measured characteristics.
Patients will be follo wed up until first occurrence of death, discontinuation, 
disenrollment, end of data, or 365 days.
The data will be displayed in a nonparametric fashion on a persistency 
curve (a Kaplan–Meier curve) with discontinuation considered as 
elimination. 
Unmatched Cohort
Rates andrisks ( proportion of patients )with the outcomes for each 
exposure group will be reported among the unmatched cohort.
Matched Cohort
Rates and risks (proportion of patients) with the outcomes for each 
exposure group will be reported among the matched cohort.
Logistic regression will be used to calculate the propensity to initiate
Olodaterol/Tiotropium Bromide versus Umeclidinium/Vilanterol .The 
propensity score will then be used to identify up to 2 initiators of 
Umeclidinium/Vilanterol for each initiator of Olodaterol/Tiotropium
Bromide with the same propensity score ( ±a caliper of 5%) as the 
corresponding initiator of Olodaterol/Tiotropium Bromide .
Boehringer Ingelheim Page 14of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Name of company:
Boehringer Inge lheim International 
GmbH
Name of finished medicinal product:
Stiolto® Respimat®; Anoro® Ellipta®
Name of active ingredient:
Olodaterol and Tiotropium Bromide 
(ATC R03AL06) ;Umeclidinium and 
Vilanterol (ATC R03AL03)
Protocol date: Study number: Version/Revision:Version/Revision 
date:
22November 2019 1237-00 90 1.0 NA
Cox proportional hazard regression model will be used to assess the
relative rate(or hazard) of the outcome in patients treated with
Olodaterol/Tiotropium Bromide compared to patients treated with 
Umeclidinium/Vilanterol during the one -year follow -up. Crude HRs and 
95% CI s will be reported for the matched cohorts
.
Among the matched cohort, relative risks with 95% CIs will also be 
reported, as assessed by conditional logistic regression.
Relative rates and risks will also be reported using standard multivariable 
regression.
Sensitivity Analyses
Restrict the 60-day allowable grace period used to define the 
discontinuation outcome to 30 days .
Increase the 60- day allowable grace period used to define the 
discontinuation outcome to 90days.
Start the p atient identification period on21 May 2015 immediately 
upon FDA approval .
Exclude patients with A COS. Patients with a sthma only but not 
COPD are still excluded from cohort.
Milestones:-Feasibility assessment Sept 2018 (done)
-    Draft s tudy protocol Dec 2018
-    Final study protocol Apr2019
-Results tables available May 2019
- 1stAbstract submitted Jun   2019 
(ERS 2019,  ISPOR or AMCP )
   -    Manuscript submitted Q22019
Boehringer Ingelheim Page 15of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct20155. AMENDMENTS AND UPDAT ES
Not Applicable
6. MILESTONES
Milestone Planned Date
Draft Protocol 17 December 2018
Protocol Revisions 22February  2019*
Start of Implementation 01March 2019
Preliminary  Result Tables 15 March 2019
Final Result Tables and 
Documentation of 
Implementation26April 2019
*Pending time for approval and suggested changes proposed b y BI
7. RATIONALE AND BACKGR OUND
Chronic obstructive pulmonary disease (COPD) is a common disease characterized by  airway  
obstruction confirmed b y spirometry, often including small airway  obstruction , chronic 
bronchitis and emph ysema ( Barnes 2015). No known medications can reverse COPD, but 
regular maintenance treatments can help manage sy mptoms , reduce frequency  of COPD 
exacerbations and improve 
health-related qualit y of life. Inhaled ther apies are the cornerstone 
of COPD disease management approaches. The aim of inhaled therap y is to deliver agents 
directly  to the lungs, thereby  offering benefits while minimizing the potential for treatment -
related adverse effects ( Braido 2016 ).
Adherence to obstructive lung disease therapies involves patients initiating their prescribed 
therap y, implementing it as prescribed (i.e. correctly  administering the prescribed dose at the 
physician directed frequency ), and persisting with treatment ( Braido 2016; Mäkelä 2013). 
Central to the therapeutic benefit of inhaled therapies is their successful administration which 
requires patients to have knowledge and understanding of (and ability  to implement) the 
appropriate inhaler technique required to optimize both the dispensed and administered doses 
(Braido 2016 ). Inspiratory  capabilities of patients with COPD are affected by  increasing 
static and dy namic hy perinflation and weakening of the respiratory  muscles, causing many  
patients to have peak inspiratory  flow rat es that are suboptimal to use many dry -powder 
inhalers (DPIs) ( Sohini 2017 ). This paradoxical situation may  lead to improper inhalation 
that prevents successful drug delivery  to the lungs, which may  affect treatment effectiveness . 
On the other hand, soft mist inhalers (SMI) force a metered dose of drug solution through a 
precise nozzle to deliver consistent and reliable doses to the lungs with each actuation ( Dalby
2004) and may  help preserve benefits in patients with diminished peak inspiratory  flow rates . 
Stiolto ® Respimat®, a combination of Olodaterol and Tiotropium Bromide delivered via soft 
mist inhaler (SMI ), was approved in May  2015 in the US and July  2015 in the EU (marketed 
Boehringer Ingelheim Page 16of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015as Spiolto in the EU). Anoro® Ellipta®, a combination of Umeclidinium and Vilanterol
delivered via dry  powder inhaler (DPI), was approved in December 2013 in the US and in 
February  2014 in the EU. Both products are maintenance therapies consisting of a 
combination of long- acting muscarinic antagonists (LAMA) and long -acting bet a agonists 
(LABA). However, the question of whether different devices (DPI and SMI) play  a role in 
treatment persistence remains to be answered. 
This study  seeks to compare the treatment persistence of two drugs in same drug class 
(LAMA/LABA as a fixed d ose combination [FDC ]) delivered through different devices (a 
DPI and a SMI) within an administrative claims database in the US.
8. RESEARCH QUESTION AN D OBJECTIVES
The primary  objective of the study  is to use US data to determine relative treatment
persiste nce in using Olodaterol/Tiotropium Bromide delivered with the Respimat soft mist 
inhaler andUmeclidinium/Vilanterol delivered with the Ellipta dry powder inhaler using a 
1:2 propensity  score matched analy sis.
The secondary  objectives of the study  are as follows:
Characterize new users of Olodaterol/Tiotropium Bromide and Umeclidinium/Vilanterol in 
terms of demographics, medication use, comorbidities, and other variables, before and after 
propensity  score matching.
Determine the rate and proportion of pati entsdiscontinuati ngamong new users of 
Olodaterol/Tiotropium Bromide and Umeclidinium/ Vilanterol.
Determine the relative rate and proportion of patients discontinuing between 
Olodaterol/Tiotropium Bromide and Umeclidinium/Vilanterol, using a standard mul tivariate 
analysis (If feasible).
Boehringer Ingelheim Page 17of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct20159. RESEARCH METHODS
9.1 STUDY DESIGN
The proposed stud y will utilize data from the Truven MarketScan dataset (US).
The Truven MarketScan databases are comprised of two components: the MarketScan
Commercial Claims and Encounters (CCAE) Database and the Medicare Supplemental and 
Coordination of Benefits (COB) Database. These databases capture longitudinal, individual -
level data on healthcare utilization, healthcare expenditures and plan enrollment, and contain 
integrated records for patient demographics, inpatient events, outpatient events, and 
pharmacy  dispensing of drugs. The CCAE database is a medical and drug insurance claims 
database on ~150 million patients since from 2008 unique de- identified patients that include 
active emplo yees, dependents, retirees or recipients of the Consolidated Omnibus Budget 
Reconciliation Act (COBRA), and data are drawn from large employ ers, health plans, and 
public organizations in the United States (Truven Health MarketScan® Research Databases 
2015). The MarketScan Medicare Supplemental and Coordination of Benefits (COB) 
Database contains pooled medical and drug insurance claims data of approximately  13.6 
Million unique de -identified patients (since 1996) that are M edicare -eligible retirees with 
employ er-sponsored Medicare Supplemental plans. ( Truven Health MarketScan® 
Research Databases 2015 ). 
In principle, in US when a patient goes to a pharmacy  and gets a drug dispensed, the 
pharmacy  bills the insurance carrier for the cost of that drug ( Strom 2013 ). For billing 
purposes, the pharmacy  has to identify  which medication was dispensed along with the 
dosage strength (e.g. the milligrams per tablet ) and quantity  (e.g., number of tablets, etc .). 
Analogousl y, when a pati ent goes to a hospital or to a phy sician for medical care, the 
providers of care bill the insurance carrier for the cost of the medical care, and have to justify  
the bill with a diagnosis. Using a common patient identification number for both the 
pharmacy  and the medical care claims, these elements can be linked, and anal yzed as a 
longitudinal medical record ( Strom 2013 ).
9.2 SETTING
9.2.1 Definitions
Study  Period: the period of time that includes the exclusion criteria assessment period,
baseline, cohort entry  date, and follow -up period for the study  population. This period is the 
same for all patients.
The study  period will be from 1 January  2008 to 31 March 2018, encompassing date of the 
earliest data availability  to the date of the la test data availability .
Boehringer Ingelheim Page 18of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Patient Selection Period: the period of time for which patients are eligible to enter the cohort. 
The earliest date of the patient selection period is 17 November 2015, corresponding to 180-
days after US approval date of St iolto Re spimat.
Cohort Entry  Date: Date of entry  to the initial cohort of Stiolto or Anoro users.
Baseline Period: the 180 -day period that ends 1 day  prior to the cohort entry  date used to 
assess covariate information. The baseline period will vary  between patie nts depending on 
these dates. The earliest start of the baseline period would be 21 May  2015
, the date of Stiolto 
approval (i.e. 180 day s before November 17, 2015).
Follow -Up Period: the period of time between 1 day  after the cohort entry  date to the earl iest 
occurrence of the outcome (discontinuation of refills ),or an y censoring criteria ( 365 day s, 
death, disenrollment, or end of data ). Addition of another treatment in addition to index 
treatment will not count as discontinuation.
For entry  into the study  population, patients will be required to have 180 day s of continuous 
enrolment with both medical and pharmacy coverage. Data during the baseline period will be 
used to confirm study  eligibility  and classification of incident COPD. The follow -up period 
will be used for capturing first and second maintenance therapies. This is illustrated in 
Figure 1.
Figure 1 Study  timeline for the Primary  Study  Population

Boehringer Ingelheim Page 19of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct20159.2.2 Study population
The pre -matched study  cohort will consist of patients initiating Olodaterol /Tiotropium 
Bromide or Umeclidinium/Vilanterol between 17 November 2015 and 31 March 2018. 
The following e xclusion criteria will then be applied :
Aged <40 years.
Enrolment with medical and pharmacy  coverage prior to the cohort entry  < 180 day s.
Never had COPD diagnosis on the cohort entry  date or prior to cohort entry.
A record for dispensed Olodaterol/Tiotropium Bromide delivered with Respimat inhalator or 
Umeclidinium/Vilanterol delivered with the Ellipta Inhaler during the 180 -day baseline prior 
to cohort entry .
Diagnosis of asthma an y time prior to cohort entry.
Diagnosis of lung cancer any  time prior to cohort entry .
Diagnosis of lung transplant an y time prior to cohort entry.
Figure 2 B
elow depicts the flow diagram of patients.

Boehringer Ingelheim Page 20of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Diagnosis of COPD (I CD-9: 491.*, 492.*, 496.*; ICD -10: J41.0, J41.1, J41.8, J42.*, J43.0, 
J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.9 )will be defined as the presence of an inpatient 
or outpatient claim.
Diagnosis of asthma (ICD -9: 493.*
;ICD-10: J45, J45.20, J45.21, J45.22, J 45.90*, J45.99*) 
will be defined as either 1 inpatient claim or 2 outpatient events 30-365 daysapart.
Diagnosis of lung cancer (I CD-9: 162.2, 162.3, 162.4, 162.5, 162.8, 162.9, 231.2 ; ICD-10: 
C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, 
C34.81, C34.82, C34.90, C34.91, C34.92, C7A.090, D02.20, D02.21, D02.22, Z85.118 ) will 
be defined as either 1 inpatient claim or 2 outpatient events 30- 365 day s apart.
Matched Cohort
A matched propensity  score anal ysis will be us ed to assess comparative persistence between 
the two exposure comparison groups. Logistic regression will be used to calculate the 
propensity  to initiate Olodaterol/Tiotropium Bromide versus Umeclidinium/Vilanterol given 
all covariates (except 
components o f the Charlson Comorbidity  index) listed in section 9 .3.3, 
according to the following model:
Logit (Treatment | X1, X2, … , Xn) =  β0 + β1*X1 + β2*X2 + … + βn*Xn
Any covariates which are collinear with each other will be drop ped from the anal ysis (if it 
causes failure of model to converge). The propensity  score will then be used to identify  up to 
2 initiators of Umeclidinium/Vilanterol for each initiator of Olodaterol/Tiotropium Bromide 
with the same propensit y score (± a cali per of 5%) as the corresponding initiator of 
Olodaterol/Tiotropium Bromide (Austin 2011). 
9.3 VARIABLES
9.3.1 Exposures
Exposure: Olodaterol/Tiotropium Bromide (Stiolto®) delivered with Respimat 
inhalator 
Active Comparator: Umeclidinium/Vilanterol (Anoro ®) delivered with the Ellipta 
Inhaler
Both exposures will be identified via NDC Generic Name and NDC Brand Name.
9.3.2 Outcomes
9.3.2.1 Primary  outcome
Discontinuation
The primary  outcome of interest is discontinuation of index treatment (Olodaterol /Tiotropium 
Bromide or Umeclidinium/Vilanterol), defined as persistence (i.e. no refill claim within 60 
Boehringer Ingelheim Page 21of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015days[not involving treatment switch , nor death] (allowable grace p eriod) after end of <n> 
days suppl y)during follow -up.
Censoring
Patients will be ce nsoring if they  did not discontinue their index treatment but had an 
occurrence of an y of the following: 365 day s of follow -up without discontinuation, death, 
disenrollment, end of data.
9.3.2.2 Secondary  outcomes
Not applicable.
9.3.3 Covariates
Covariates will be ide ntified based on data recorded within 180 days prior to or on the index 
date (date of dispensing/initiation of the exposure), unless otherwise specified. If multiple 
measurements are made in the baseline period, then the most recent measurement will be 
used. 
Covariates will be used to predict propensit y scores in later analyses. Absolute and relative 
frequencies of each covariate will also be reported in Table Shells 1 and 2 (see Annex 5).
Detailed descriptions of the listed co variates can be found in Annex 3 and 4.
Demographics
Age on index date
Sex (Male, Female)
Region (Northeast, North Central, South, West, Unknown, Missing
Insurance Ty pe (Commercial, Medicare, Missing)
Year of Cohort Entry  (First Year, Second Year)
Concomitant Medications
Oral Corticosteroids
Short acting muscarinic antagonist (SAMA)
Short acting beta agonist (SABA)
Long acting muscarinic antagonist (LAMA)
Long acting beta agonist (LABA)
Inhaled cortico steroid (ICS)
LAMA / LABA combination (that is not Stiolto or Anoro)
LABA / ICS combination
LAMA / LABA / ICS combination
NSAIDs
Antihistamines
Opioids
Oral antibiotics
Antidiabetic Agents (not including insulin)
Boehringer Ingelheim Page 22of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Insulin (basal or mealtime)
Methotrexate
Statins
Antihy pertensives
Anticoagulants
Anti- psychotic/anti -depressives/anxiolytic
Oxygen therapy
Comorbidities/Symptoms
History  of All-Cause Hospitalization
History  of Emergency  Department Visit
History  of Hospitalization due to Respiratory  Condition
Acute M yocardial Infarction
Angina Pectoris
Peripheral Vascular Disease
Heart Failure
Hypertension
Upper Respiratory  Infection
Lower Respiratory  Infection
Cardiac Arrh ythmias
Cerebrovascular Disease
All Cancers (except nonmelanoma skin cancer )
Allergic Rhi nitis
Chronic Sinusitis
Bronchiectasis
Pneumonia
Chronic Bronchitis
Exertional Breathlessness
Anxiety
Dementia
Depression
Osteoporosis
Charlson Dey o Comorbidity  Index
Acute Liver Injury  or Failure
Chronic Kidney  Disease (without ESRD)
End Stage Renal Disease
Rheumatic Disease
Peptic Ulcer Disease
Gastroesophageal Reflux Disease
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
HIV/AIDS
Hemiplegia or Paraplegia
Boehringer Ingelheim Page 23of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Lifestyle
Smoking -related claim
Vaccination for Influenza
Vaccination for Pneumococcus
Respiratory Function Procedures/Tests
Pulmonary  function tests
Six-minute walk test
Chest X -ray
High resolution chest CT
9.4 DATA SOURCES
The proposed stud y will utilize data from Truven MarketScan data (US).
The Truven MarketScan databases capture longitudinal, individual- level administrative 
claims data from the United States. The data available for the study  includes three 
components of MarketScan: the Commercial Claims and Encounters (CCAE) Database, the 
Medicare Supplemental and Coordination of Benefits D
atabase (MDCR), and the Medicaid 
Database. Patients in the databases include active employ ees, dependents, retirees, COBRA 
recipients, and Medicare or Medicaid enrollees. Data were drawn from large employ ers, 
health plans, and public organizations in the U nited States. The following tables of the 
MarketScan databases were available for anal ysis: Enrol lment Detail, I npatient Admissions, 
Inpatient Services, Outpatient Services, Outpatient Pharmaceutical Claims, and L ong Term 
Care. These tables provide informa tion on plan enro llment, healthcare utilization and 
expenditures, demographics, and integrated records for inpatient events, outpatient events, 
and pharmacy  dispensings. Data 
are available from January  1, 2008 to March 31, 2018, and 
represent approximately 162million patients.
9.5 STUDY SIZE
There are 14,751 new users of Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol 
between 17 November 2015 and 31 March 2018 who satisfied the inclusion criteria. Among 
them, 3,889 initiated Olodaterol/Tiotropium Bromide and 10,862 initiated 
Umeclidinium/Vilanterol).
9.6 DATA MANAGEMENT
Dataset
The Truven Health MarketScan database is comprised of fully  adjudicated and paid claims 
records of integrated longitudinal enrolment, inpatient, outpatient and drug data from 
multiple payors that has been standardized and de- identified prior to use for the anal ysis. The 
statistical analy sis will be conducted using the  Evidence Platform.

Boehringer Ingelheim Page 24of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Drug Duration
Unless otherwise noted, drug event duration was calculated from the “Day ’s Supply ” field, 
and in cases where this field was 0, the duration was assumed to be 1 day . 
Handling of Missing Data
Missing data that occurs in covariates or descriptive variables will be classified as its own 
level. In addition, a feasibi lity assessment before beginning the anal yses will be done, and 
variables with >75 % missing values will be excluded from all analy ses, other than baseline 
characteristics. If a variable is left with only  one level other than missing, the variable will be 
excluded completely  from all analy ses.
9.7 DATA ANALYSIS
9.7.1 Main analysis
For all analy ses, variables will be reported as follows :
Continuous variables (e.g., age) will be presented as means (with standard deviation, 
SD) and/or medians (with interquartile range, IQR).
Categorical variables (e.g., sex) will be presented as absolute and relative frequencies.
All results will have two digits following the decimal point.
9.7.1.1 Descriptive Analy sis
All variables specified in section 9 .3.3will be reported. For demographic and lifesty le 
variables, the value recorded on the cohort entry  date will be reported, otherwise the most 
recent known value will be reported. Presence of comorbidities and use of concomitant 
medication use will be determined bas ed whether they  ever occurred within the 180- day 
baseline period preceding the index date. Differences in the confounder distributions were 
inspected for successful confounder balance of measured characteristics.
9.7.1.2 Rates and Risks
Rate of Discontinuation of Olodaterol/Tiotropium Bromide or
Umeclidinium/ Vilanterol in the Pre -matched Cohort
Among the pre -matched cohort, rates of discontinuation of Olodaterol/Tiotropium Bromide 
or Umeclidinium/Vilanterol will be reported as the number of events divided by  the number 
of person -years at risk.
Risk of Discontinuation of Olodaterol/Tiotropium Bromide or 
Umeclidinium/Vilanterol in the Pre- matched Cohort
Among the pre -matched cohort, risk (proportion of patients) of discontinuation of 
Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol will be reported as the number 
of events divided b y the number of eligible patients at cohort entry date. 
Boehringer Ingelheim Page 25of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Discontinuation of Olodaterol/Tiotropium Bromide or Umeclidinium/ Vilanterol in the 
Post-matched Cohort
Among the p ost-matched cohort, rates of discontinuation of Olodaterol/Tiotropium Bromide 
or Umeclidinium/Vilanterol will be reported as the number of events divided by the number 
of person -years at risk.
Discontinua tion of Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol in the 
Post-matched Cohort
Among the p ost-matched cohort, risk (proportion of patients) of discontinuation of 
Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol will be reported as the number 
of events divided b y the number of eligible patients at cohort entry date. 
9.7.1.3 Comparative Persistence
Relative Rate of Discontinuation of Olodaterol/Tiotropium Bromide vs 
Umeclidinium/Vilanterol in the Unmatched Cohort
Multiv ariable Cox proportional hazards models with all variables (except components of the 
Charlson Comorbidity  index) in section 9 .3.3. will be used to estimate the hazard ratios 
(HRs) and 95% CIsfor Olodaterol/Tiotropium Bromide c ompared to patients treated with 
Umeclidinium/Vilanterol during follow -up for incident discontinuations, according to the 
following model:
h(t | Treatment , X1, … , X n) = h(t 0)*exp(β1*Treatment + β 1*X2+ … + β n*Xn+1)
Where treatment canbe 1=Stiolto or 0= Anoro and t = time to discontinuation
Relative Risk of Discontinuation of Olodaterol/Tiotropium Bromide vs 
Umeclidinium/Vilanterol in the Unmatched Cohort
Multivariable logistic regression will be used to assess relative risk of discontinuation and 
95% CIsfor Olodaterol/Tiotropium Bromide compared to patients treated with 
Umeclidinium/Vilanterol during follow -up for incident discontinuations, according to the 
following model using all covariates (except components of the Cha rlson Comorbidity  index) 
in section 9 .3.3.:
Logit (Discontinuation=1 |  Treatment , X1, X2, … , X n) = β 0+ β 1*Treatment + β 1*X2+ … + 
βn*Xn+1
Relative Rateof Discontinuation of Olodaterol/Tiotropium Bromide vs 
Umeclidinium/Vilanterol in the M atched Cohort
Cox proportional hazards models with treatment as the only  independent variable will be 
used to estimate the hazard ratios (HRs) and 95% CIsfor Olodaterol/Tiotropium Bromide 
Boehringer Ingelheim Page 26of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015compared to patients treated with Umeclidinium/Vilanterol during follow- up for incident 
discontinuations, according to the following model:
h(t|Treatment, X) = h 0(t)*exp( β1*Treatment)
Where treatment can be 1 =Stiolto or 0=Anoro and t = time to discontinuation
Relative Risk of Discontinuation of Olodaterol/Tiotropium Bromide vs 
Umeclidinium/Vilanterol in the Matched Cohort
Logistic regression will be used to assess relative risk of discontinuation and 95% CI sfor
Olodaterol/Tiotropium Bromide compared to patients treated with Umeclidinium/Vilanterol 
during follow -up for incident discontinuations, according to the following model:
Logit(Discontinuation=1 |  Matched set) = β 1*Treatment + stratum(i)
Where treatment can be 1=Stiolto or 0=Anoro and t = time to discontinuation
9.7.2 Sensitivity Analysis
Four sensitivity  anal yses will be 
conducted. For these anal yses, in the interest of reducing the 
number of additional tables, only the descriptive statistics for the matched population (Annex 
Table 2), and primary  results ( Annex Tables 4 and 5) will be reported.
Two sensitivity  anal yses will be conducted to evaluate the robustness of the outcome 
definition:
1.Use of a 30-day Grace Period
Restrict the 60-day allowable grace period used to define the discontinuation outcome to 30
days to allow a gap of one month . This sensitivity  anal ysis may  be useful if the 60-day grace 
period is too lenient, as the usual day ’s suppl y of Stiolto is 30 days.
2.Use of a 90-day Grace Period
Since neither the Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol drug products 
are available as generic formulation s, the relatively  high price of these medications may lead 
some patients to space out their doses to greater than the recommended dosing schedule or 
use one puff instead of two to prolong their medication supply . Patients may  also neglect to 
take their medications due to forgetfulness or because they  become less symptomatic. Thus, 
we will also increase the 60-dayallowable grace period used to define the discontinuation 
outcome
,to 90 day s.
Two sensitivity  anal yses will be conducted in an attempt to increase the sample size:
3.Start Patient I dentification Period in 
21 May  2015
Boehringer Ingelheim Page 27of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015The primary  identification period st arts 180 day s after Stiolto Respimat was approved b y 
FDA for use in the US ( 21 May 2015) on 17 November 2015. This sensitivity  cohort will 
start the patient identification period immediately  upon FDA approval on 21 May  2015.
4.Do Not Exclude Patients with Diagnosis of 
ACOS from theCohort
Patients in the primary  analy siswith diagnosis of asthma (regardless of whether or not they  
have COPD) will be excluded to restrict to patients with only COPD. It is possible that some 
patients with COPD may have a claim for asthma prior to their COPD diagnosis as part of 
their COPD diagnostic work -up, rather than an ongoing asthma diagnosis. Therefore, this 
sensitivity  cohort will not exclude patients with a 
previous diagnosis of asthma .Note that 
patients with only  asthm a but no COPD will still be excluded from this cohort.
9.8 QUALITY CONTROL
will build measures for cohort inclusion, outcomes and covariates. Some of the 
measure algorithms will be based on those collaboratively  developed for another respiratory -
related protocol with clinical input from external pulmonology  experts . When availab le, 
algorithms that have been validated in administrative databases will be used. When validated 
algorithms are not available, coding criteria will be based on clinical input and through 
searches of medical claim coding s ystems.
All measures created, cohorts developed, statistical anal yses implemented, and tables 
completed will undergo quality  control review b y at least 1 additional analyst or scientist 
under the supervision of the senior scientist.
This protocol will be strictly  followed in the stud y.However, measure definitions may  
undergo modification if determined to be scientifically  sensible. 
All changes to this protocol 
will be documented in protocol amendments.
The study  protocol has been written following the Code of Conduct by  the European Net work 
of Centres for Pharmacoepidemiology  and Pharmacovigilance (ENCePP) [ R15-4870] that 
provides a set of rules and principles for post -authorisation studies with regard to the best 
practices and transparency , thereby  promoting scientific independence of such studies. The 
study  will be registered to the ENCePP’s E -register and the results will also be published on 
the same site.
The study  protocol also follows the key  elements of the Guideline for Good 
Pharmacoepidemiology Practices (GPP) b y International Society  for Pharmacoepidemiology  
[R11-4318 ], and the recent draft Guidance for Industry  and FDA Staff “Best Practices for 
Conducting and Reporting Pharmacoepidemiologic Safet y Studies Using Elec tronic 
Healthcare Data Sets” [ R15-4859].
Quality  controls include checks for the validity  and logical content of codes and checks for 
missing values and variables. I n order to control for potential inconsistencies and errors, a ll 

Boehringer Ingelheim Page 28of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015variables will be tabulated. I n addition, the distribution of each variable will be examined. 
Extreme observations with values larger than ± 3 standard deviations (SD) will be examined 
as potential outliers and consequently  excluded from the dataset.
9.9 LIMITATIONS OF THE RES EARCH METHODS
This study  will be conducted using data from insurance claims and is subject to certain 
limitations. One limitation is that these are based on a large, non -random convenience 
sample, which may  contain biases or lack genera lizability  to other populations. Data also 
come mostly  from large employ ers, and although the database also includes a large amount of 
data from health plans, data from medium and small firms may  be underrepresented.
Additionally , the Market Scan database also poses some limitations inherent to administrative 
claims data. Electronic outpatient pharmacy  dispensing records are considered accurate 
because pharmacists fill prescriptions with little room for interpretation and are reimbursed 
by insurers on the basis of detailed, complete, and accurate claims submitted electronically  
(Stergachi 1988, Lev y 2003). Pharmacy dispensing information is usually seen as the gold 
standard of drug exposure information compared to self- reported information (West 1995) or 
prescribing records in outpatient medical records (West 1994). However, drugs used during 
hospital stay s are not recorded in this data source. Claims data are subject to certain 
limitations. The presence of a claim for a filled prescription does not indicate that the 
medication was consumed or that it was taken as prescribed, and an y medications filled over -
the-counter or provided as samples by  the ph ysician will not be observed in the claims data. 
Furthermore, as with all claims- based anal yses, study  results may not be generalizable to the 
overall population as patients who have commercial health insurance may  be different from 
those with non-commercial or without (commercial) health insurance. Finally , patients are 
required not to have a claim for Olodaterol/ Tiotropium Bromide or Umeclidinium/Vilanterol
during the baseline period, but use of these medications may  have occurred prior to the start 
of the baseline period .
In the anal ytical portion of this protocol, propensity  score matching will be used to estimate 
relative persistence between the two exposures of interest. Various covariates are included in 
the prediction model of the propensit y scores, but as with all non -interventional studies, the 
potential for unmeasured and residual confounding cannot be ruled out. 
9.10 OTHER ASPECTS
Not applicable.
9.11 SUBJECTS
9.11.1 Cases
See Section 9.2.2.
Boehringer Ingelheim Page 29of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct20159.11.2 Controls
Not applicable.
9.12 BIAS
In principle, electronic outpat ient pharmacy  dispensing records are considered accurate 
because pharmacists fill prescriptions with little room for interpretation, and are reimbursed 
by insurers based on detailed, complete, and accurate claims submitted electronically  (Levy 
2003; Stergachis 1988) . Pharmacy  dispensing information is usually  seen as the gold 
standard of drug exposure information compared to self- reported information or prescribing 
records in outpatient medical records.
The population -based nature of the database will avoi d selection bias and ensure external 
validity . Confounding bias through observable covariates will be controlled for b y the design, 
which includes propensity  score matching.
To minimize misclassification of the recorded patient characteristics, previously  validated 
algorithms or code lists will be used whenever available. Code lists will be reviewed b y the 
qualified medical reviewers prior to implementation. Basic plausibility  checks will be 
implemented for continuous variables (e. g. age, etc.).
While this analy sis is designed to assess non
-persistence as an endpoint. Whether or not the 
patient actuall y complied with the prescription cannot be known. For example, a patient may 
fill a 30- day prescription, but may  only compl y with the medication for a few day s before 
truly  discontinuing, leading to an overestimation of persistence when using claims data. 
Furthermore, even if a patient did comply , they  may  administer the doses incorrectly . 
The covariates chosen in section 9 .3.3. a re hypothesized to be confounders in the relationship 
between exposure and outcome. The range and quantity  of variables selected are aimed to 
make the two exposure groups more comparable so that the interpretation of effect estimates 
may be more meaningful . 
10. PROTECTION OF HUMAN SUBJECTS
As the present stud y is a non -interventional retrospective cohort stud y, the most significant 
potential impact on the participants would be the potential for individual identification and 
loss of privacy . Patients in the Mar ketScan dataset are de -identified , such that names are not 
linked to patient I Ds. Thus, the risks to participants are expected to be minimal.
Boehringer Ingelheim Page 30of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct201511. MANAGEMENT AND REPOR TING OF ADVERSE 
EVENTS/ADVERSE REACT IONS
Data is anon ymized and extracted, anal yzed, validate d and reported in aggregate. 
There is no potential that any  employ ee of BI or agent working on behalf of BI will access 
individual patient data in which the patient may  be identified during data compilation, data 
reporting or data anal ysis.
Based on cur rent guidelines from the International Society for Pharmacoepidemiology  
[R11-4318] and the EMA [ R13- 1970], non -interventional studies such as the one described in 
this protocol, conducted using health care records, do not require expedited reporting of 
suspected adverse events/reactions. Specifically , as stated in section VI.C.1.2.1 of Guideline 
on Good Pharmacovigilance Practices (GVP), Module VI –Management and Reporting of 
Adverse Reactions to Medi cinal Products, for non- interventional study  designs, which are 
based on use of secondary  data, reporting of adverse reactions is not required .
12. PLANS FOR DISSEMINAT ING AND COMMUNICATIN G 
STUDY RESULTS
The results of the stud y will primarily  serve internal decision making for future studies on 
comparative effectiveness. These baseline results will be published as an abstract and/or 
manuscript. Conference and Journal to be decided.
Boehringer Ingelheim Page 31of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct201513. REFERENCES
13.1 PUBLISHED R EFERENCES
P04-12446 Dalby  R, Spallek M, Voshaar T. A review of the development of Respimat 
Soft Mist I nhaler. Int J Pharm. 2004 Sep 28;283(1 –2):1–9.
P13-
03077 West SL , Strom BL, Freundlich B, Normand E, Koch G, Savitz DA. 
Completeness of prescription recor ding in outpatient medical records from a 
health maintenance organization. Journal of clinical epidemiology . 
1994;47(2):165 –71.
P13-
03078 West SL , Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall 
accuracy  for prescription medications: self -report compared with database 
information. Am J Epidemiol. 1995 Nov 15;142(10):1103–12
P19-
09366 Braido F, Chry styn H, Baiardini I, Bosnic -Anticevich S, van der Molen T, 
Dandurand RJ, et al. “Trying, But Failing” -The Role of Inhaler Technique 
and Mode of Delive ry in Respiratory  Medication Adherence. J Allergy  Clin 
Immunol Pract. 2016 Oct;4(5):823 –32.
P19-
09661 Barnes PJ, Burney  PGJ, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et 
al. Chronic obstructive pulmonary  disease. Nat Rev Dis Primers. 2015 Dec 
3;1:1507 6.
R11-4318 Guidelines for Good Pharmacoepidemiology Practices (GPP) (revision 2: 
April 2007). http://www.pharmacoepi.org/resources/guidelines_08027.cfm 
(access date: 13 September 2011) ; Bethesda: International Society  for 
Pharmacoepidemiology (ISPE) (2007)
R13-1970 European Medicines Agency (EMA), Heads of Medicines Agencies (HMA)
Guideline on good pharmacovigilance practices (GVP): module VI -
management and reporting of adverse reactions to medicinal products (22 June 
2012,EMA/873138/2011).h ttp://www.ema.europa.eu/docs/en_GB/document_l
ibrary /Scientific_guideline/2012/0 6/WC500129135.pdf (access date: 7 May  
2013) ; European Medicines Agency (EMA), Heads of Medicines Agencies 
(HMA) (2012) 
R13-2804 Stergachis AS. Record linkage studies for post marketing drug surveillance: 
data quality  and validity  considerations. Drug Intell Clin Pharm. 1988 
Feb;22(2):157–61.
R13-2806 Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding 
accuracy  of administrative drug claims in the Ontario Drug Benefit database. 
Can J Clin Pharmacol. 2003 Summer;10(2):67
–71.
R15-
4859 Guidance for industry  and FDA staff: best practices for conducting and 
reporting pharmacoepidemiologic safety  studies using electronic healthcare 
data (May  2013, drug safety ). 
http://w ww.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformati
on/guida nces/ucm243537.pdf (access date: 28 August 2015) ; U.S. 
Department of Health and Human Services, Food and Drug Administration, 
Boehringer Ingelheim Page 32of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Center for Drug Evaluation and Research (CDER), Center f or Biologics 
Evaluation and Research (CBER) (2013)
R15-4870 European Medicines Agency  (EMA)The ENCePP code of conduct for 
scientific independence and transparency  in the conduct of 
pharmacoepidemiological and pharmacovigilance studies (L ondon, 21 
November 2011, EMA/929209/2011).
http://www.encepp.eu/code_of_conduct/documents/CodeofConduct_Rev2.pdf 
(access date: 28 August 2015) ; L ondon: European Medicines Agency  (EMA), 
European Network of Centres for Pharmacoepidemiology  and 
Pharmacovigilance (ENCePP) (2011)
R18-
2599 Austin PC. An I ntroduction to Propensity  Score Methods for Reducing the 
Effects of Confounding in Observational Studies. Multivariate behavioral 
research. 2011 May ;46(3):399 –424.
R18-
2765 Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled 
therapies, health outcomes and costs in patients with asthma and COPD. 
Respir Med. 2013 Oct;107(10):1481–90.
R19-
3352 Ghosh S, Ohar JA, Drummond MB. Peak Inspiratory  Flow Rate in Chronic 
Obstructive Pulmonary  Disease: Im plications for Dry  Powder Inhalers. Journal 
of Aerosol Medicine and Pulmonary  Drug Delivery . 2017 Sep 21;30(6):381 –7
R19-
3355 Truven Health MarketScan Research Databases. Commercial claims and 
encounters Medicare Supplemental and Coordination of Benefits [ Internet]. 
2015. Available from: https://www.entnet.org/content/marketscan-
commerical -claims- and-encountersmarketscan -medicare -supplemental -and-
coordination .
R19-3476 Strom BL . Overview of automated databases in pharmacoepidemiology . In a 
Book Strom BL, Ki mmel SE, Henness yS, editors. Pharmacoepidemiology . 
Hoboken: John Wiley  & Sons, I ncorporated.
13.2 UNPUBLISHED REFERENC ES
Not Applicable
Boehringer Ingelheim Page 33of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015ANNEX 1. LIST OF STA ND-ALONE DOCUMENTS
NumberDocument 
Reference 
NumberDate Title
1 Annex 1 19 April 2019 List of stand- alone documents
2 Annex 2 19 April 2019 ENCEPP Checklist for study protocols
3 Annex 3 19 April 2019 List of medication measure definitions
4 Annex 4 19 April 2019List of comorbidity and other measure 
definitions
5 Annex 5 19 April 2019 Table shells and proposed figures
Boehringer Ingelheim Page 34of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015ANNEX 2. ENCEPP CHECKLIST FOR STUDY PROT OCOLS
Not Applicable
Boehringer Ingelheim Page 35of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 2019 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companie s
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015ANNEX 3. LIST OF MEDICATION M EASURE DEFINITIONS
Name Components
CorticosteroidsBetam ethasone, *beclometasone (beclomethasone), cortisone acetate, dexamethasone, hydrocortisone, 
methylprednisolone, prednisolone, prednisone, triamcinolone, deflazacort, fludrocortisone
Short Acting Beta Agonist Albuterol, metaproterenol, levalbuterol, pirbuterol, terbutaline
Short Acting Muscarinic 
AntagonistIpratropium
Long Acting Muscarinic 
Antagonist (LAMA)Umeclidinium, glycopyrrolate, tiotropium, aclidinium, Incruse, Seebri, Spiriva, Tudorza
Long Acting Beta Agonist 
(LABA)Indacaterol, arformoterol, formoterol, salmeterol, olodaterol, Arcapta, Atimos, Brovana, Perforomist, Serevent, 
Striverdi, Foradil
Inhaled CorticosteroidsFlunisolide, budesonide, mometaso ne, ciclesonide, fluticasone, beclomethasone, Aerobid, Aerospan, Alvesco, 
Armonair, Arnuity, Asmanex, Azmacort, Flixotide, Flovent, Pulmicort, Qvar
LAMA / LABA combination indacaterol/glycopyrrolate, glycopyrrolate/formoterol, Utibron, Bevespi
LABA / ICS combinationFluticasone/vilanterol, budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Advair, Symbicort, 
Breo, Dulera
LAMA / LABA / ICS 
combinationFluticasone/umeclidinium/vilanterol, Trelegy
NSAIDsPhenylbutazone, sulindac, tolmeti n, diclofenac, etodolac, ketorolac, piroxicam, meloxicam, ibuprofen, naproxen, 
ketoprofen, fenoprofen, suprofen, flurbiprofen, oxaprozin, mefanamic acid, meclofenamic acid, celecoxib, rofecoxib, 
valdecoxib, nabumetone, glucosamine sulfate
Boehringer Ingelheim Page 36of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015OpioidsMorphine , hydromorphone, oxycodone, dihydrocodeine, fentanyl, pentazocine, buprenorphine, butorphanol, nalbuphine, 
tramadol, tapentadol, hydrocodone, codeine
Antihistamines /Antiallergenic
sDiphenhydramine, clemastine, carbinoxamine, doxylamine, brompheniramine, dexchlorpheniramine, pheniramine, 
tripelennamine, promethazine, thiethylperazine, cyclizine, chlorcyclizine, cetirizine, cyproheptadine, phenindamine, 
triprolidine, azatadine, astemizole, terfenadine, loratadine, ketotifen, azelastine, levocabastine, epina stine, fexofenadine, 
desloratadine, ephedrine, phenylephrine, oxymetazoline, xylometazoline, naphazoline, nedocromil
Oral AntibioticsDem eclocycline, doxycycline, chlortetracycline, oxytetracycline, tetracycline, minocycline, tigecycline, 
chloramphenicol, ampicillin, carbenicillin, amoxicillin, bacampicillin, mezlocillin, piperacillin, ticarcillin, dicloxacillin, 
cloxacillin, oxacillin, flucloxacillin, nafcillin, sulbactam, tazobactam, cefazolin, cefadroxil, cefoxitin, cefuroxime, 
cefamandole, cefaclor, ce fotetan, loracarbef, cefprozil, cefotaxime, ceftazidime, ceftriaxone, ceftizoxime, cefixime, 
cefoperazone, cefpodoxime, ceftibuten, cefdinir, cefditoren, cefepime, aztreonam, meropenem, ertapenem, doripenem, 
trimethoprim, sulfapyridine, sulfanilamide, sulf athiazole, sulfamethoxazole, sulfadiazine, sulfamerazine, sulfapyridine, 
sulfanilamide, sulfathiazole, sulfadiazine, sulfamethoxazole, sulfachlorpyridazine, sulfamerazine, sulfacetamide, 
erythromycin, troleandomycin, clarithromycin, azithromycin, dirithrom ycin, telithromycin, clindamycin, lincomycin, 
quinupristin/dalfopristin, streptomycin, tobramycin, gentamicin, kanamycin, neomycin, amikacin, netilmicin, 
paromomycin, ofloxacin, ciprofloxacin, enoxacin, norfloxacin, lomefloxacin, sparfloxacin, grepafloxaci n, levofloxacin, 
trovafloxacin, moxifloxacin, gemifloxacin, gatifloxacin, delafloxacin, cinoxacin, vancomycin, telavancin, dalbavancin, 
oritavancin, colistin, polymyxin b, metronidazole, tinidazole, nitrofurantoin, fosfomycin, spectinomycin, methenamine, 
mandelic acid, linezolid, daptomycin, bacitracin, tedizolid, novobiocin
Diabetes Mellitus MedicationsSulfonylureas (chlorpropamide, tolbutamide, tolazamide, glipizide, gliquidone, acetohexamide), biguanides (metformin), 
thiazolidinediones (troglitazone, r osiglitazone, pioglitazone), alpha- glucosidase inhibitors (acarbose, miglitol), 
meglitinides (repaglinide, nateglinide, mitiglinide), DPP -4 inhibitors (gitagliptin, vildagliptin, saxagliptin, alogliptin, 
linagliptin), GLP -1 receptor agonists (exenatide, li raglutide, lixisenatide, albiglutide, dulaglutide, semaglutide), SGLT -2 
inhibitors (dapagliflozin, canagliflozin, empagliflozin)
Insulin Rapid -acting insulin, short -acting insulin, intermediate -acting insulin, long -acting insulin
Methotrexate Methotrexat e
AnticoagulantsVitamin K antagonists (phenindione, warfarin), heparins (heparin, antithrombin III, dalteparin, enoxaparin, danaparoid, 
tinzaparin), platelet aggregation inhibitors (clopidogrel, ticlopidine, dipyridamole, epoprostenol, iloprost, abciximab, 
eptifibatide, tirofiban, treprostinil, prasugrel, cilostazol, ticagrelor, cangrelor, vorapaxar, selexipag), direct thrombin 
Boehringer Ingelheim Page 37of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015inhibitors (desirudin, lepirudin, argatroban, bivalirudin, dabigatran etexilate), direct factor Xa inhibitors (rivaroxaba n, 
apixaban, edoxaban), anticoagulant enzymes (anistreplase, urokinase, reteplase, drotrecogin alfa, tenecteplase), 
defibrotide, fondaparinux)
Statins Atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, pitavastatin, cerivastatin
AntihypertensivesAngiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta -blockers, calcium channel 
blockers, diuretics, alpha -blockers, alpha -beta blockers, vasiodilators
Anti- psychotics/
Anti- depressives/Anxioly ticsDesipramine, clomipramine, trimipramine, amitriptyline, nortriptyline, protriptyline, doxepin, amoxapine, maprotiline, 
fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram, isocarboxazid, phenelzine, tranylcypromine, 
tryptophan, t razodone, nefazodone, minaprine, mirtazapine, bupropion, venlafaxine, milnacipran, duloxetine, 
desvenlafaxine, vilazodone, vortioxetine, selegiline, chlorpromazine, promazine, acepromazine, triflupromazine, 
fluphenazine, perphenazine, prochlorperazine, tri fluoperazine, thioridazine, mesoridazine, pipotiazine, haloperidol, 
droperidol, molindone, ziprasidone, lurasidone, thiothixene, pimozide, loxapine, clozapine, olanzapine, quetiapine, 
asenapine, lithium, risperidone, aripiprazole, paliperidone, iloperidone , cariprazine, brexpiprazole, pimavanserin, 
diazepam, chlordiazepoxide, oxazepam, lorazepam, clobazam, alprazolam, halazepam, hydroxyzine, meprobamate, 
buspirone
Oxygen Therapy Oxygen
Boehringer Ingelheim Page 38of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015ANNEX 4. LIST OF COMORBIDITY, SYMPTOMS A ND OTHER MEASURE DEF INITIONS
Name Definition
Comorbidities /Symptoms
History of All -Cause 
HospitalizationAll inpatient events
History of 
Emergency 
Department Visit1 Outpatient
Place of Service is any of:
oEmergency Room -Hospital
oUrgent Care Facility
History of 
Hospitalization due to 
Respiratory 
Condition1 Inpatient
Diagnosis Code (Principal), ICD -9is any of: { “415.1”, “415.11”, “415.12”, “415.13”, “415.19”, “465”, “465.0”, “465.8”, 
“465.9”, “466”, “466.0”, “466.1”, “466.11”, “466.19”, “480.0”, “480.1”, “480.2”, “480.3”, “48 0.8”, “480.9”, “481”, “482.0”, 
“482.1”, “482.2”, “482.30”, “482.31”, “482.32”, “482.39”, “482.40”, “482.41”, “482.42”, “483.0”, “483.1”, “483.8”, “484.1”, 
“484.3”, “484.5”, “484.6”, “484.7”, “484.8”, “486”, “487.0”, “488.01”, “488.11”, “488.81”, “490”, “49 1”, “491.0”, “491.1”, 
“491.2”, “491.20”, “491.21”, “491.22”, “491.8”, “491.9”, “492.0”, “492.8”, “493.0”, “493.00”, “493.01”, “493.02”, “493.1”, 
“493.10”, “493.11”, “493.12”, “496”, “515”, “516.3”, “516.30”, “516.31”, “516.32”, “516.8”, “516.9”, “518.81”, “518.83”, 
“518.84” }
Diagnosis Code (Principal), ICD -10is any of: { “A01.03”, “A02.22”,  “A37.01”,  “A37.11”, “A37.81”,  “A37.91”, “A40.3”, 
“A50.04”, “A54.84”, “B01.2”, “B05.2”, “B06.81”, “B77.81”, “B95.3”, “B96.0”, “B96.1”, “I26.9”, “I26.90”, “I26.92”, “I26.99”, 
“J06”, “J06.0”, “J06.9”, “J09.X1”, “J09.X2”, “ J10.0”, “J10.00”, “J10.01”, “J10.08”, “J10.1”, “J11.0”, “J11.00”, “J11.08”, “J11.1”, 
“J12”, “J12.0”, “J12.1”, “J12.2”, “J12.3”, “J12.8”, “J12.81”, “J12.89”, “J12.9”, “J13”, “J14”, “J15”, “J15.0”, “J15.1”, “J15.2”, 
“J15.20”, “J15.21”, “J15.211”, “J15.212”, “J15.29”, “J15.3”, “J15.4”, “J15.5”, “J15.6”, “J15.7”, “J15.8”, “J15.9”, “J16”, “J16.0”, 
“J16.8”, “J17”, “J18”, “J18.0”, “J18.1”, “J18.2”, “J18.8”, “J18.9”, “J20”, “J20.0”, “J20.1”, “J20.2”, “J20.3”, “J20.4”, “J20. 5”, 
“J20.6”, “J20.7”, “J20.8”, “J20.9”, “J21.0”, “J22”, “J39”, “J39.3”, “J39.8”, “J39.9”, “J40”, “J41”, “J41.0”, “J41.1”, “J41.8”, “J42”, 
“J43”, “J43.0”, “J43.1”, “J43.2”, “J43.8”, “J43.9”, “J44.0”, “J45”, “J45.2”, “J45.20”, “J45.21”, “J45.22”, “J45.3”, “J45.30”,
“J45.31”, “J45.32”, “J45.4”, “J45. 40”, “J45.41”, “J45.42”, “J45.5”, “J45.50”, “J45.51”, “J45.52”, “J45.9”, “J45.90”, “J45.901”, 
“J45.902”, “J45.909”, “J45.99”, “J45.991”, “J45.998”, “J47.0”, “J68.0”, “J84.11”, “J84.111”, “J84.116”, “J84.117”, “J84.2”, 
Boehringer Ingelheim Page 39of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“J85.1”, "J96", "J96.9", "J96.90", "J9 6.91", "J96.92", “J96.0”, “J96.00”, “J96.01”, “J96.02”, “J96.1”, “J96.10”, “J96.11”, 
“J96.12”, “J96.2”, “J96.20”, “J96.21”, “J96.22”, “J98”, “J98.2”, “J98.3”, “J98.8” }
Acute Myocardial 
Infarction1 Inpatient or 1 Outpatient
Diagnosis Code (Position 1), ICD-9is any of: { “410”, “410.0”, “410.00”, “410.01”, “410.1”, “410.10”, “410.11”, “410.2”, 
“410.20”, “410.21”, “410.3”, “410.30”, “410.31”, “410.4”, “410.40”, “410.41”, “410.5”, “410.50”, “410.51”, “410.6”, “410.60”,
“410.61”, “410.7”, “410.70”, “410.71”, “410.8”, “410.80”, “410.81”, “410.9”, “410.90”, “410.91” }
Diagnosis Code (Principal), ICD -10is any of: { “I21.09”, “I21.11”, “I21.19”, “I21.29”, “I21.3”, “I21.4”, “I22.0”, “I22.1”, 
“I22.2”, “I22.8”, “I22.9” }
Angina Pectoris1 Inpatient or 2 Outpatient (30 –365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “413”, “413.0”, “413.1”, “413.9” }
Diagnosis Code (Any Position), ICD -10is any of: { “I20.1”, “I20.8”, “I20.9” }
Peripheral Vascular 
Disease1 Inpatient or 2 Outpatient (30 –365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “440”, “440.0”, “440.1”, “440.2”, “440.20”, “440.21”, “440.22”, “440.23”, 
“440.24”, “440.29”, “440.3”, “440.30”, “440.31”, “440.32”, “440.4”, “440.8”, “440.9”, “441”, “441.0”, “441.00 ”, “441.01”, 
“441.02”, “441.03”, “441.1”, “441.2”, “441.3”, “441.4”, “441.5”, “441.6”, “441.7”, “441.9”, “442”, “442.0”, “442.1”, “442.2”,
“442.3”, “442.8”, “442.81”, “442.82”, “442.83”, “442.84”, “442.89”, “442.9”, “443.1”, “443.2”, “443.21”, “443.22”, “4 43.23”, 
“443.24”, “443.29”, “443.8”, “443.81”, “443.82”, “443.89”, “443.9”, “447.1”, “785.4”, “38.13”, “38.14”, “38.16”, “38.18”, 
“38.33”, “38.34”, “38.36”, “38.38”, “38.43”, “38.44”, “38.46”, “38.48”, “39.22”, “39.23”, “39.24”, “39.25”, “39.26”, “39.29” }
Diagnosis Code (Any Position), ICD -10is any of: { “I70.0”, “I70.1”, “I70.209”, “I70.219”, “I70.229”, “I70.25”, “I70.269”, 
“I70.299”, “I70.399”, “I70.499”, “I70.599”, “I70.8”, “I70.90”, “I70.91”, “I70.92”, “I71.00”, “I71.01”, “I71.02”, “I71.03”, “I 71.1”,
“I71.2”, “I71.3”, “I71.4”, “I71.5”, “I71.6”, “I71.8”, “I71.9”, “I72.0”, “I72.1”, “I72.2”, “I72.3”, “I72.4”, “I72.8”, “I72.9”, “I73.1”, 
“I73.81”, “I73.89”, “I73.9”, “I77.1”, “I77.71”, “I77.72”, “I77.73”, “I77.74”, “I77.79”, “I79.8”, “I96” }
Boehringer Ingelheim Page 40of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Heart Failure1 Inpatient
Diagnosis Code (Any Position), ICD -9is any of: { “428”, “428.0”, “428.1”, “428.2”, “428.20”, “428.21”, “428.22”, 
“428.23”, “428.3”, “428.30”, “428.31”, “428.32”, “428.33”, “428.4”, “428.40”, “428.41”, “428.42”, “428.43”, “428.9” 
}
Diagnosis Code (Any Position), ICD -10is any of: { “I50”, “I50.9”, “I50.2”, “I50.20”, “I50.21”, “I50.22”, “I50.23”, 
“I50.3”, “I50.30”, “I50.31”, “I50.32”, “I50.33”, “I50.4”, “I50.40”, “I50.41”, “I50.42”, “I50.43” }
Hypertension1 Inpatient or 2 Outpatient (30 – 365days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “401”, “401.0”, “401.1”, “401.9”, “402”, “402.0”, “402.00”, 
“402.1”, “402.10”, “402.9”, “402.90”, “403”, “403.0”, “403.00”, “403.01”, “403.1”, “403.10”, “403.11”, “403.9”, 
“403.90”, “403.91”, “404”, “404.0”, “404.00”, “404.01”, “404.02”, “404.03”, “404.1”, “404.10”, “404.11”, “404.12”, 
“404.13”, “404.9”, “404.90”, “404.91”, “404.92”, “404.93”, “405”, “405.0”, “405.01”, “405.09”, “405.1”, “405.11”, 
“405.19”, “405.9”, “405.91”, “405.99” }
Diagno sis Code (Any Position), ICD -10is any of: { “I10”, “I11.9”, “I12.0”, “I12.9”, “I13.0”, “I13.10”, “I13.11”, 
“I13.2”, “I15.0”, “I15.8” }
Upper Respiratory 
Infection (with no 
sinusitis)1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “034”, “034.0”, “034.1”, “460”, “461”, “461.0”, “461.1”, “461.2”, 
“461.3”, “461.8”, “461.9”, “462”, “463”, “464”, “464.0”, “464.00”, “464.01”, “464.1”, “464.10”, “464.11”, “464.2”, 
“464.20”, “464.21”, “464.3”, “464.30”, “464.3 1”, “464.4”, “464.5”, “464.50”, “464.51”, “465”, “465.0”, “465.8”, 
“465.9”, “487”, “487.1”, “487.8” }
Diagnosis Code (Any Position), ICD -10is any of: { “J03.00”, “J03.01”, “A38”, “A38.8”, “A38.9”, “J00”, “J01”, 
“J01.9”, “J01.90”, “J01.8”, “J01.80”, “J01.0”, “J01.00”, “J01.01”, “J32.0”, “J01.1”, “J01.10”, “J01.11”, “J32.1”, 
“J01.2”, “J01.20”, “J01.21”, “J32.2”, “J01.3”, “J01.30”, “J01.31”, “J32.3”, “J02”, “J02.8”, “J02.9”, “J04”, “J04.0”, 
“J05”, “J05.0”, “J04.1”, “J04.10”, “J04.11”, “J04.2”, “J05.1”, “J05.10”, “J05.11”, “J04.3”, “J04.30”, “J04.31”, “J06”, 
“J06.9”, “J11.89”, “J11.8”, “J11.1”, “J11”, “J10.89”, “J10.8”, “J10.1”, “J10.00”, “J10.0” , “J10”, “J09.X2”, “J09.X9”, 
Boehringer Ingelheim Page 41of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“J09.X”, “J09” }
Lower Respiratory 
Infection1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “466”, “466.0”, “466.1”, “466.11”, “466.19” }
Diagnosis Code (Any Position), ICD -10is any of: { “J20.9”, “J21.0”, “J21.8”, “J22” }
Cardiac Arrhythmias1 Inpatient or 1 Outpatient
Diagnosis Code (Principal), ICD -9is any of: { “427”, “427.0”, “427.1”, “427.2”, “427.3”, “427.31”, “427.32”, 
“427.4”, “427.41”, “427.42”, “427.5”, “427.6”, “427.60”, “427.61”, “427.69”, “427.8”, “427.81”, “427.89”, “427.9” }
Diagnosis Code (Position 1), ICD -10is any of: { “I46.9”, “I47.1”, “I47.2”, “I47.9”, “I48.91”, “I48.92”, “I49.01”, 
“I49.02”, “I49.1”, “I49.3”, “I49.40”, “I49.49”, “I49.5”, “I49. 8”, “I49.9”, “R00.1” }
Cerebrovascular 
Disease1 Inpatient
Diagnosis Code (Any Position), ICD -9is any of: { “430”, “431”, “432”, “432.0”, “432.1”, “432.9”, “433”, “433.0”, 
“433.01”, “433.1”, “433.11”, “433.2”, “433.21”, “433.3”, “433.31”, “433.8”, “433.81”, “433.9”, “433.91”, “434”, 
“434.0”, “434.01”, “434.1”, “434.11”, “434.9”, “434.90”, “434.91”, “435”, “435.8”, “435.9”, “436” }
Diagnosis Code (Any Position), ICD -10is any of: { “G45”, “G45.8”, “G45.9”, “I60”, “I60.0”, “I60.00”, “I60.01”, 
“I60.0 2”, “I60.1”, “I60.10”, “I60.11”, “I60.12”, “I60.2”, “I60.20”, “I60.21”, “I60.22”, “I60.3”, “I60.30”, “I60.31”, 
“I60.32”, “I60.4”, “I60.5”, “I60.50”, “I60.51”, “I60.52”, “I60.6”, “I60.7”, “I60.8”, “I60.9”, “I61”, “I61.0”, “I61.1”, 
“I61.2”, “I61.3”, “I61.4”, “I61.5”, “I61.6”, “I61.8”, “I61.9”, “I62”, “I62.0”, “I62.00”, “I62.01”, “I62.02”, “I62.03”, 
“I62.1”, “I62.9”, “I63”, “I63.0”, “I63.00”, “I63.01”, “I63.011”, “I63.012”, “I63.019”, “I63.02”, “I63.03”, “I63.031”, 
“I63.032”, “I63.039”, “I63.09”, “I63.1”, “I63 .10”, “I63.11”, “I63.111”, “I63.112”, “I63.119”, “I63.12”, “I63.13”, 
“I63.131”, “I63.132”, “I63.139”, “I63.19”, “I63.2”, “I63.20”, “I63.21”, “I63.211”, “I63.212”, “I63.219”, “I63.22”, 
“I63.23”, “I63.231”, “I63.232”, “I63.239”, “I63.29”, “I63.3”, “I63.30”, “I63.31”, “I63.311”, “I63.312”, “I63.319”, 
“I63.32”, “I63.321”, “I63.322”, “I63.329”, “I63.33”, “I63.331”, “I63.332”, “I63.339”, “I63.34”, “I63.341”, “I63.342”, 
“I63.349”, “I63.39”, “I63.4”, “I63.40”, “I63.41”, “I63.411”, “I63.412”, “I63.419”, “I63.42”, “I 63.421”, “I63.422”, 
Boehringer Ingelheim Page 42of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“I63.429”, “I63.43”, “I63.431”, “I63.432”, “I63.439”, “I63.44”, “I63.441”, “I63.442”, “I63.449”, “I63.49”, “I63.5”, 
“I63.50”, “I63.51”, “I63.511”, “I63.512”, “I63.519”, “I63.52”, “I63.521”, “I63.522”, “I63.529”, “I63.53”, “I63.531”, 
“I63.532”, “I63.539”, “I63.54”, “I63.541”, “I63.542”, “I63.549”, “I63.59”, “I63.6”, “I63.8”, “I63.9”, “I65”, “I65.0”, 
“I65.01”, “I65.02”, “I65.03”, “I65.09”, “I65.1”, “I65.2”, “I65.21”, “I65.22”, “I65.23”, “I65.29”, “I65.8”, “I65.9”, 
“I66”, “I66.0”, “I66.01”, “I66.02”, “I66.03”, “I66.09”, “I66.1”, “I66.11”, “I66.12”, “I66.13”, “I66.19”, “I66.2”, 
“I66.21”, “I66.22”, “I66.23”, “I66.29”, “I66.3”, “I66.8”, “I66.9” }
All Cancers (except 
nonmelanoma skin 
cancer)1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “140”, “140.0”, “140.1”, “140.3”, “140.4”, “140.5”, “140.6”, 
“140.8”, “140.9”, “141”, “141.0”, “141.1”, “141.2”, “141.3”, “141.4”, “141.5”, “141.6”, “141.8”, “141.9”, “142”, 
“142.0”, “142.1”, “142.2”, “142.8” , “142.9”, “143”, “143.0”, “143.1”, “143.8”, “143.9”, “144”, “144.0”, “144.1”, 
“144.8”, “144.9”, “145”, “145.0”, “145.1”, “145.2”, “145.3”, “145.4”, “145.5”, “145.6”, “145.8”, “145.9”, “146”, 
“146.0”, “146.1”, “146.2”, “146.3”, “146.4”, “146.5”, “146.6”, “ 146.7”, “146.8”, “146.9”, “147”, “147.0”, “147.1”, 
“147.2”, “147.3”, “147.8”, “147.9”, “148”, “148.0”, “148.1”, “148.2”, “148.3”, “148.8”, “148.9”, “149”, “149.0”, 
“149.1”, “149.8”, “149.9”, “150”, “150.0”, “150.1”, “150.2”, “150.3”, “150.4”, “150.5”, “150 .8”, “150.9”, “151”, 
“151.0”, “151.1”, “151.2”, “151.3”, “151.4”, “151.5”, “151.6”, “151.8”, “151.9”, “152”, “152.0”, “152.1”, “152.2”, 
“152.3”, “152.8”, “152.9”, “153”, “153.0”, “153.1”, “153.2”, “153.3”, “153.4”, “153.5”, “153.6”, “153.7”, “153.8”, 
“153.9”, “154”, “154.0”, “154.1”, “154.2”, “154.3”, “154.8”, “155”, “155.0”, “155.1”, “155.2”, “156”, “156.0”, 
“156.1”, “156.2”, “156.8”, “156.9”, “157”, “157.0”, “157.1”, “157.2”, “157.3”, “157.4”, “157.8”, “157.9”, “158”, 
“158.0”, “158.8”, “158.9”, “159”, “159.0”, “159.1”, “159.8”, “159.9”, “160”, “160.0”, “160.1”, “160.2”, “160.3”, 
“160.4”, “160.5”, “160.8”, “160.9”, “161”, “161.0”, “161.1”, “161.2”, “161.3”, “161.8”, “161.9”, “162”, “162.0”, 
“162.2”, “162.3”, “162.4”, “162.5”, “162.8”, “162.9”, “163”, “163.0 ”, “163.1”, “163.8”, “163.9”, “164”, “164.0”, 
“164.1”, “164.2”, “164.3”, “164.8”, “164.9”, “165”, “165.0”, “165.8”, “165.9”, “170”, “170.0”, “170.1”, “170.2”, 
“170.3”, “170.4”, “170.5”, “170.6”, “170.7”, “170.8”, “170.9”, “171”, “171.0”, “171.2”, “171.3”, “171.4”, “171.5”, 
“171.6”, “171.7”, “171.8”, “171.9”, “174”, “174.0”, “174.1”, “174.2”, “174.3”, “174.4”, “174.5”, “174.6”, “174.8”, 
“174.9”, “175”, “175.0”, “175.9”, “176”, “176.0”, “176.1”, “176.2”, “176.3”, “176.4”, “176.5”, “176.8”, “176.9”, 
“179”, “180”, “180.0”, “180.1”, “180.8”, “180.9”, “181”, “182”, “182.0”, “182.1”, “182.8”, “183”, “183.0”, “183.2”, 
“183.3”, “183.4”, “183.5”, “183.8”, “183.9”, “184”, “184.0”, “184.1”, “184.2”, “184.3”, “184.4”, “184.8”, “184.9”, 
“185”, “186”, “186.0”, “186.9”, “18 7”, “187.1”, “187.2”, “187.3”, “187.4”, “187.5”, “187.6”, “187.7”, “187.8”, 
“187.9”, “188”, “188.0”, “188.1”, “188.2”, “188.3”, “188.4”, “188.5”, “188.6”, “188.7”, “188.8”, “188.9”, “189”, 
Boehringer Ingelheim Page 43of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“189.0”, “189.1”, “189.2”, “189.3”, “189.4”, “189.8”, “189.9”, “190 ”, “190.0”, “190.1”, “190.2”, “190.3”, “190.4”, 
“190.5”, “190.6”, “190.7”, “190.8”, “190.9”, “191”, “191.0”, “191.1”, “191.2”, “191.3”, “191.4”, “191.5”, “191.6”, 
“191.7”, “191.8”, “191.9”, “192”, “192.0”, “192.1”, “192.2”, “192.3”, “192.8”, “192.9”, “193” , “194”, “194.0”, 
“194.1”, “194.3”, “194.4”, “194.5”, “194.6”, “194.8”, “194.9”, “195”, “195.0”, “195.1”, “195.2”, “195.3”, “195.4”, 
“195.5”, “195.8”, “172”, “172.0”, “172.1”, “172.2”, “172.3”, “172.4”, “172.5”, “172.6”, “172.7”, “172.8”, “172.9”, 
“196”, “ 196.0”, “196.1”, “196.2”, “196.3”, “196.5”, “196.6”, “196.8”, “196.9”, “197”, “197.0”, “197.1”, “197.2”, 
“197.3”, “197.4”, “197.5”, “197.6”, “197.7”, “197.8”, “198”, “198.0”, “198.1”, “198.2”, “198.3”, “198.4”, “198.5”, 
“198.6”, “198.7”, “198.8”, “198.81”, “198.82”, “198.89”, “199”, “199.0”, “199.1”, “199.2”, “200”, “200.0”, “200.00”, 
“200.01”, “200.02”, “200.03”, “200.04”, “200.05”, “200.06”, “200.07”, “200.08”, “200.1”, “200.10”, “200.11”, 
“200.12”, “200.13”, “200.14”, “200.15”, “200.16”, “200.17”, “200.1 8”, “200.2”, “200.20”, “200.21”, “200.22”, 
“200.23”, “200.24”, “200.25”, “200.26”, “200.27”, “200.28”, “200.3”, “200.30”, “200.31”, “200.32”, “200.33”, 
“200.34”, “200.35”, “200.36”, “200.37”, “200.38”, “200.4”, “200.40”, “200.41”, “200.42”, “200.43”, “200. 44”, 
“200.45”, “200.46”, “200.47”, “200.48”, “200.5”, “200.50”, “200.51”, “200.52”, “200.53”, “200.54”, “200.55”, 
“200.56”, “200.57”, “200.58”, “200.6”, “200.60”, “200.61”, “200.62”, “200.63”, “200.64”, “200.65”, “200.66”, 
“200.67”, “200.68”, “200.7”, “200 .70”, “200.71”, “200.72”, “200.73”, “200.74”, “200.75”, “200.76”, “200.77”, 
“200.78”, “200.8”, “200.80”, “200.81”, “200.82”, “200.83”, “200.84”, “200.85”, “200.86”, “200.87”, “200.88”, “201”, 
“201.0”, “201.00”, “201.01”, “201.02”, “201.03”, “201.04”, “201. 05”, “201.06”, “201.07”, “201.08”, “201.1”, 
“201.10”, “201.11”, “201.12”, “201.13”, “201.14”, “201.15”, “201.16”, “201.17”, “201.18”, “201.2”, “201.20”, 
“201.21”, “201.22”, “201.23”, “201.24”, “201.25”, “201.26”, “201.27”, “201.28”, “201.4”, “201.40”, “201 .41”, 
“201.42”, “201.43”, “201.44”, “201.45”, “201.46”, “201.47”, “201.48”, “201.5”, “201.50”, “201.51”, “201.52”, 
“201.53”, “201.54”, “201.55”, “201.56”, “201.57”, “201.58”, “201.6”, “201.60”, “201.61”, “201.62”, “201.63”, 
“201.64”, “201.65”, “201.66”, “201.67”, “201.68”, “201.7”, “201.70”, “201.71”, “201.72”, “201.73”, “201.74”, 
“201.75”, “201.76”, “201.77”, “201.78”, “201.9”, “201.90”, “201.91”, “201.92”, “201.93”, “201.94”, “201.95”, 
“201.96”, “201.97”, “201.98”, “202”, “202.0”, “202.00”, “202.01”, “202 .02”, “202.03”, “202.04”, “202.05”, “202.06”, 
“202.07”, “202.08”, “202.1”, “202.10”, “202.11”, “202.12”, “202.13”, “202.14”, “202.15”, “202.16”, “202.17”, 
“202.18”, “202.2”, “202.20”, “202.21”, “202.22”, “202.23”, “202.24”, “202.25”, “202.26”, “202.27”, “2 02.28”, 
“202.3”, “202.30”, “202.31”, “202.32”, “202.33”, “202.34”, “202.35”, “202.36”, “202.37”, “202.38”, “202.4”, 
“202.40”, “202.41”, “202.42”, “202.43”, “202.44”, “202.45”, “202.46”, “202.47”, “202.48”, “202.5”, “202.50”, 
“202.51”, “202.52”, “202.53”, “ 202.54”, “202.55”, “202.56”, “202.57”, “202.58”, “202.6”, “202.60”, “202.61”, 
“202.62”, “202.63”, “202.64”, “202.65”, “202.66”, “202.67”, “202.68”, “202.7”, “202.70”, “202.71”, “202.72”, 
“202.73”, “202.74”, “202.75”, “202.76”, “202.77”, “202.78”, “202.8”, “202.80”, “202.81”, “202.82”, “202.83”, 
Boehringer Ingelheim Page 44of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“202.84”, “202.85”, “202.86”, “202.87”, “202.88”, “202.9”, “202.90”, “202.91”, “202.92”, “202.93”, “202.94”, 
“202.95”, “202.96”, “202.97”, “202.98”, “203”, “203.0”, “203.00”, “203.01”, “203.02”, “203.1”, “203.10”, “2 03.11”, 
“203.12”, “203.8”, “203.80”, “203.81”, “203.82”, “204”, “204.0”, “204.00”, “204.01”, “204.02”, “204.1”, “204.10”, 
“204.11”, “204.12”, “204.2”, “204.20”, “204.21”, “204.22”, “204.8”, “204.80”, “204.81”, “204.82”, “204.9”, 
“204.90”, “204.91”, “204.92 ”, “205”, “205.0”, “205.00”, “205.01”, “205.02”, “205.1”, “205.10”, “205.11”, “205.12”, 
“205.2”, “205.20”, “205.21”, “205.22”, “205.3”, “205.30”, “205.31”, “205.32”, “205.8”, “205.80”, “205.81”, 
“205.82”, “205.9”, “205.90”, “205.91”, “205.92”, “206”, “206. 0”, “206.00”, “206.01”, “206.02”, “206.1”, “206.10”, 
“206.11”, “206.12”, “206.2”, “206.20”, “206.21”, “206.22”, “206.8”, “206.80”, “206.81”, “206.82”, “206.9”, 
“206.90”, “206.91”, “206.92”, “207”, “207.0”, “207.00”, “207.01”, “207.02”, “207.1”, “207.10”, “207.11”, “207.12”, 
“207.2”, “207.20”, “207.21”, “207.22”, “207.8”, “207.80”, “207.81”, “207.82”, “208”, “208.0”, “208.00”, “208.01”, 
“208.02”, “208.1”, “208.10”, “208.11”, “208.12”, “208.2”, “208.20”, “208.21”, “208.22”, “208.8”, “208.80”, 
“208.81”, “208.8 2”, “208.9”, “208.90”, “208.91”, “208.92”, “V10.82” }
Diagnosis Code (Any Position), ICD -10is any of: { “C00.0”, “C00.1”, “C00.2”, “C00.3”, “C00.4”, “C00.5”, 
“C00.6”, “C00.8”, “C01”, “C02.0”, “C02.1”, “C02.2”, “C02.3”, “C02.4”, “C02.8”, “C02.9”, “C03.0”, “C03.1”, 
“C03.9”, “C04.0”, “C04.1”, “C04.8”, “C04.9”, “C05.0”, “C05.1”, “C05.2”, “C05.9”, “C06.0”, “C06.1”, “C06.2”, 
“C06.89”, “C06.9”, “C07”, “C08.0”, “C08.1”, “C08.9”, “C09.0”, “C09.1”, “C09.9”, “C10.0”, “C10.1”, “C10.2”, 
“C10.3”, “C10.4”, “C10.8”, “C10 .9”, “C11.0”, “C11.1”, “C11.2”, “C11.3”, “C11.8”, “C11.9”, “C12”, “C13.0”, 
“C13.1”, “C13.2”, “C13.8”, “C13.9”, “C14.0”, “C14.2”, “C14.8”, “C15.3”, “C15.4”, “C15.5”, “C15.8”, “C15.9”, 
“C16.0”, “C16.1”, “C16.2”, “C16.3”, “C16.4”, “C16.5”, “C16.6”, “C16.8”, “C16.9”, “C17.0”, “C17.1”, “C17.2”, 
“C17.3”, “C17.8”, “C17.9”, “C18.0”, “C18.1”, “C18.2”, “C18.3”, “C18.4”, “C18.5”, “C18.6”, “C18.7”, “C18.8”, 
“C18.9”, “C19”, “C20”, “C21.0”, “C21.1”, “C21.8”, “C22.0”, “C22.1”, “C22.2”, “C22.7”, “C22.8”, “C22.9”, “C23”, 
“C24.0”, “C24.1”, “C24.8”, “C24.9”, “C25.0”, “C25.1”, “C25.2”, “C25.3”, “C25.4”, “C25.7”, “C25.8”, “C25.9”, 
“C26.0”, “C26.1”, “C26.9”, “C30.0”, “C30.1”, “C31.0”, “C31.1”, “C31.2”, “C31.3”, “C31.8”, “C31.9”, “C32.0”, 
“C32.1”, “C32.2”, “C32.3”, “C32.8”, “C32.9 ”, “C33”, “C34.00”, “C34.10”, “C34.2”, “C34.30”, “C34.80”, “C34.90”, 
“C37”, “C38.0”, “C38.1”, “C38.2”, “C38.3”, “C38.4”, “C38.8”, “C39.0”, “C39.9”, “C40.00”, “C40.10”, “C40.20”, 
“C40.30”, “C41.0”, “C41.1”, “C41.2”, “C41.3”, “C41.4”, “C41.9”, “C43.0”, “C43. 10”, “C43.20”, “C43.30”, 
“C43.31”, “C43.39”, “C43.4”, “C43.59”, “C43.60”, “C43.70”, “C43.8”, “C43.9”, “C46.0”, “C46.1”, “C46.2”, 
“C46.3”, “C46.4”, “C46.50”, “C46.7”, “C46.9”, “C47.8”, “C48.0”, “C48.1”, “C48.2”, “C48.8”, “C49.0”, “C49.10”, 
“C49.20”, “C49.3” , “C49.4”, “C49.5”, “C49.6”, “C49.8”, “C49.9”, “C50.019”, “C50.029”, “C50.119”, “C50.219”, 
“C50.319”, “C50.419”, “C50.519”, “C50.619”, “C50.819”, “C50.919”, “C50.929”, “C51.0”, “C51.1”, “C51.2”, 
Boehringer Ingelheim Page 45of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“C51.9”, “C52”, “C53.0”, “C53.1”, “C53.8”, “C53.9”, “C54.0”, “C54.1”, “C54.2”, “C54.3”, “C54.8”, “C54.9”, “C55”, 
“C56.9”, “C57.00”, “C57.10”, “C57.20”, “C57.3”, “C57.4”, “C57.7”, “C57.8”, “C57.9”, “C58”, “C60.0”, “C60.1”, 
“C60.2”, “C60.8”, “C60.9”, “C61”, “C62.00”, “C62.10”, “C62.90”, “C63.00”, “C63.10”, “C63.2”, “C 63.7”, “C63.8”, 
“C63.9”, “C64.9”, “C65.9”, “C66.9”, “C67.0”, “C67.1”, “C67.2”, “C67.3”, “C67.4”, “C67.5”, “C67.6”, “C67.7”, 
“C67.8”, “C67.9”, “C68.0”, “C68.1”, “C68.8”, “C68.9”, “C69.00”, “C69.10”, “C69.20”, “C69.30”, “C69.40”, 
“C69.50”, “C69.60”, “C69.80” , “C69.90”, “C70.0”, “C70.1”, “C70.9”, “C71.0”, “C71.1”, “C71.2”, “C71.3”, “C71.4”, 
“C71.5”, “C71.6”, “C71.7”, “C71.8”, “C71.9”, “C72.0”, “C72.1”, “C72.50”, “C72.9”, “C73”, “C74.90”, “C75.0”, 
“C75.1”, “C75.2”, “C75.3”, “C75.4”, “C75.5”, “C75.8”, “C75.9”, “ C76.0”, “C76.1”, “C76.2”, “C76.3”, “C76.40”, 
“C76.50”, “C76.8”, “C77.0”, “C77.1”, “C77.2”, “C77.3”, “C77.4”, “C77.5”, “C77.8”, “C77.9”, “C78.00”, “C78.1”, 
“C78.2”, “C78.39”, “C78.4”, “C78.5”, “C78.6”, “C78.7”, “C78.89”, “C79.00”, “C79.11”, “C79.19”, “C79.2 ”, 
“C79.31”, “C79.32”, “C79.49”, “C79.51”, “C79.52”, “C79.60”, “C79.70”, “C79.81”, “C79.82”, “C79.89”, “C80.0”, 
“C80.1”, “C80.2”, “C81.00”, “C81.01”, “C81.02”, “C81.03”, “C81.04”, “C81.05”, “C81.06”, “C81.07”, “C81.08”, 
“C81.09”, “C81.10”, “C81.11”, “C81.1 2”, “C81.13”, “C81.14”, “C81.15”, “C81.16”, “C81.17”, “C81.18”, “C81.19”, 
“C81.20”, “C81.21”, “C81.22”, “C81.23”, “C81.24”, “C81.25”, “C81.26”, “C81.27”, “C81.28”, “C81.29”, “C81.30”, 
“C81.31”, “C81.32”, “C81.33”, “C81.34”, “C81.35”, “C81.36”, “C81.37”, “C 81.38”, “C81.39”, “C81.40”, “C81.41”, 
“C81.42”, “C81.43”, “C81.44”, “C81.45”, “C81.46”, “C81.47”, “C81.48”, “C81.49”, “C81.70”, “C81.71”, “C81.72”, 
“C81.73”, “C81.74”, “C81.75”, “C81.76”, “C81.77”, “C81.78”, “C81.79”, “C81.90”, “C81.91”, “C81.92”, “C81.93” , 
“C81.94”, “C81.95”, “C81.96”, “C81.97”, “C81.98”, “C81.99”, “C82.90”, “C82.91”, “C82.92”, “C82.93”, “C82.94”, 
“C82.95”, “C82.96”, “C82.97”, “C82.98”, “C82.99”, “C83.10”, “C83.11”, “C83.12”, “C83.13”, “C83.14”, “C83.15”, 
“C83.16”, “C83.17”, “C83.18”, “C83.19”, “C83.30”, “C83.31”, “C83.32”, “C83.33”, “C83.34”, “C83.35”, “C83.36”, 
“C83.37”, “C83.38”, “C83.39”, “C83.50”, “C83.51”, “C83.52”, “C83.53”, “C83.54”, “C83.55”, “C83.56”, “C83.57”, 
“C83.58”, “C83.59”, “C83.70”, “C83.71”, “C83.72”, “C83.73”, “C83.74”, “C83.75”, “C83.76”, “C83.77”, “C83.78”, 
“C83.79”, “C83.80”, “C83.81”, “C83.82”, “C83.83”, “C83.84”, “C83.85”, “C83.86”, “C83.87”, “C83.88”, “C83.89”, 
“C84.00”, “C84.01”, “C84.02”, “C84.03”, “C84.04”, “C84.05”, “C84.06”, “C84.07”, “C84.08”, “C84.09”, “C84.1 0”, 
“C84.11”, “C84.12”, “C84.13”, “C84.14”, “C84.15”, “C84.16”, “C84.17”, “C84.18”, “C84.19”, “C84.40”, “C84.41”, 
“C84.42”, “C84.43”, “C84.44”, “C84.45”, “C84.46”, “C84.47”, “C84.48”, “C84.49”, “C84.60”, “C84.61”, “C84.62”, 
“C84.63”, “C84.64”, “C84.65”, “C 84.66”, “C84.67”, “C84.68”, “C84.69”, “C84.70”, “C84.71”, “C84.72”, “C84.73”, 
“C84.74”, “C84.75”, “C84.76”, “C84.77”, “C84.78”, “C84.79”, “C84.93”, “C85.80”, “C85.81”, “C85.82”, “C85.83”, 
“C85.84”, “C85.85”, “C85.86”, “C85.87”, “C85.88”, “C85.89”, “C88.8”, “C90.00”, “C90.01”, “C90.02”, “C90.10”, 
“C90.11”, “C90.12”, “C90.20”, “C90.21”, “C90.22”, “C90.30”, “C90.31”, “C90.32”, “C91.00”, “C91.01”, “C91.02”, 
“C91.10”, “C91.11”, “C91.12”, “C91.40”, “C91.41”, “C91.90”, “C91.91”, “C91.92”, “C91.Z0”, “C91.Z1”, “C91. Z2”, 
Boehringer Ingelheim Page 46of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“C92.00”, “C92.01”, “C92.02”, “C92.10”, “C92.11”, “C92.12”, “C92.20”, “C92.21”, “C92.22”, “C92.30”, “C92.31”, 
“C92.32”, “C92.40”, “C92.41”, “C92.42”, “C92.50”, “C92.51”, “C92.52”, “C92.90”, “C92.91”, “C92.92”, “C92.Z0”, 
“C92.Z1”, “C92.Z2”, “C93.00”, “ C93.01”, “C93.02”, “C93.10”, “C93.11”, “C93.12”, “C93.90”, “C93.91”, “C93.92”, 
“C93.Z0”, “C93.Z1”, “C93.Z2”, “C94.00”, “C94.01”, “C94.02”, “C94.20”, “C94.21”, “C94.22”, “C94.30”, “C94.31”, 
“C94.32”, “C94.80”, “C94.81”, “C94.82”, “C95.00”, “C95.01”, “C95.02 ”, “C95.10”, “C95.11”, “C95.12”, “C95.90”, 
“C95.91”, “C95.92”, “C96.0”, “C96.4”, “C96.9”, “C96.A”, “C96.Z”, “D03.0”, “D03.10”, “D03.11”, “D03.12”, 
“D03.20”, “D03.21”, “D03.22”, “D03.30”, “D03.39”, “D03.4”, “D03.51”, “D03.52”, “D03.59”, “D03.60”, “D03.61”, 
“D03.62”, “D03.70”, “D03.71”, “D03.72”, “D03.8”, “D03.9”, “D45”, “D03”, “D03.1”, “D03.2”, “D03.3”, “D03.5”, 
“D03.6”, “D03.7”, “C43”, “C43.1”, “C43.11”, “C43.12”, “C43.2”, “C43.21”, “C43.22”, “C43.3”, “C43.5”, “C43.51”, 
“C43.52”, “C43.6”, “C43.61”, “C43.62” , “C43.7”, “C43.71”, “C43.72”, “Z85.820” }
Allergic Rhinitis1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “477”, “477.0”, “477.1”, “477.2”, “477.8”, “477.9” }
Diagnosis Code (Any Position), ICD -10is any of: { “J30”, “J30.1”, “J30.2”, “J30.5”, “J30.8”, “J30.81”, “J30.89”, 
“J30.9” }
Chronic Sinusitis1 Inpatient or 2 Outpatient (30 –365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “473”, “473.0”, “473.1”, “473.2”, “473.3”, “473.8 ”, “473.9” }
Diagnosis Code (Any Position), ICD -10is any of: { “J32”, “J32.0”, “J32.1”, “J32.2”, “J32.3”, “J32.4”, “J32.8”, 
“J32.9” }
Bronchiectasis1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “011.5”, “011.50”, “011.51”, “011.52”, “011.53”, “011.54”, 
“011.55”, “011.56”, “494”, “494.0”, “494.1”, “748.61” }
Diagnosis Code (Any Position), ICD -10is any of: { “J47.1”, “J47.9”, “Q33.4”, “J47”, “J47.0” }
Boehringer Ingelheim Page 47of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Pneumonia1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “003.22”, “020.3”, “020.4”, “020.5”, “021.2”, “022.1”, “031.0”, 
“039.1” , “052.1”, “055.1”, “073.0”, “083.0”, “112.4”, “114.0”, “114.4”, “114.5”, “115.05”, “115.15”, “115.95”, 
“130.4”, “136. 3”, “480.0”, “480.1”, “480.2”, “480.3”, “480.8”, “480.9”, “481”, “482”, “482.0”, “482.1”, “482.2”, 
“482.3”, “482.30”, “482.31”, “482.32”, “482.39”, “482.4”, “482.40”, “482.41”, “482.42”, “482.49”, “482.8”, 
“482.81”, “482.82”, “482.83”, “482.84”, “482.89”, “482.9”, “483”, “483.0”, “483.1”, “483.8”, “484”, “484.1”, 
“484.3”, “484.5”, “484.6”, “484.7”, “484.8”, “485”, “486”, “487”, “487.0”, “487.1”, “487.8”, “517.1” }
Diagnosis Code (Any Position), ICD -10is any of: { “A01.03”, “A02.22”, “A20.2”, “A21.2”, “A22.1”, “A31.0”, 
“A37.01”, “A37.11”, “A37.91”, “A43.0”, “A49.2”, “B01.2”, “B05.2”, “B06.81”, “B25.0”, “B37.1”, “B38.0”, “B38.1”, 
“B38.2”, “B39.0”, “B39.1”, “B39.2”, “B44.0”, “B58.3”, “B59”, “B77.81”, “J09”, “J09.X”, “J09.X1”, “J09.X2”, 
“J09.X9”, “J10”, “J10.0 ”, “J10.00”, “J10.01”, “J10.08”, “J10.1”, “J10.8”, “J10.89”, “J11”, “J11.0”, “J11.00”, 
“J11.08”, “J11.8”, “J11.89”, “J12.0”, “J12.1”, “J12.2”, “J12.3”, “J12.81”, “J12.89”, “J12.9”, “J13”, “J14”, “J15.0”, 
“J15.1”, “J15.20”, “J15.211”, “J15.212”, “J15.29”, “ J15.3”, “J15.4”, “J15.5”, “J15.6”, “J15.7”, “J15.8”, “J15.9”, 
“J16.0”, “J16.8”, “J17”, “J18.0”, “J18.1”, “J18.8”, “J18.9” }
Chronic Bronchitis1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “491”, “491.0”, “491.1”, “491.2”, “491.20”, “491.21”, “491.22”, 
“491.8”, “491.9” }
Diagnosis Code (Any Position), ICD -10is any of: { “J41”, “J41.0”, “J41.1”, “J41.8”, “J42” }
Exertional 
Breathlessness1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosi s Code (Any Position), ICD -10is any of: { “R06.0*” }
Diagnosis Code (Any Position), ICD -9is any of: { “786.0” }
Boehringer Ingelheim Page 48of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Anxiety1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “293.84”, “300.0”, “300.00”, “300.02”, “300.09”, “309.21”, 
“309.24”, “309.28”, “313.0” }
Diagnosis Code (Any Position), ICD -10is any of: { “F06.4”, “F41.1”, “F41.8”, “F41.9”, “F43.22”, “F43.23”, 
“F93.0”, “F93.8”, "F40", "F40.8", "F40.9", "F41", "F41.0", "F41.3" }
Dementia1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “290.0”, “290.1”, “290.10”, “290.11”, “290.12”, “290.13”, 
“290.2”, “290.20”, “290.21”, “290.3”, “290.4”, “290.40”, “290.41”, “290.42”, “290.43”, “291.2”, “292.82”, “294.0”, 
“294.1”, “294.10”, “294.11”, “294.8”, “331.0”, “331.1”, “331.11”, “331.19”, “331.2”, “331.7”, “331.8”, “331.81”, 
“331.82”, “331.83”, “331.89”, “331.9”, “797” }
Diagnosis Code (Any Position), ICD -10is any of: { “F01.50”, “F01.51”, “F02. 80”, “F02.81”, “F03.90”, “F04”, 
“F05”, “F06.0”, “F06.8”, “F10.27”, “F19.97”, “G30.9”, “G31.01”, “G31.09”, “G31.1”, “G31.83”, “G31.84”, 
“G31.89”, “G31.9”, “G93.7”, “G94”, “R41.81”, "F32", "F32.8", "F33", "F33.8" }
Generic Name is any of: { “DONEPEZIL HCL”, “GALANTAMINE HBR”, “RIVASTIGMINE”, “MEMANTINE 
HCL” }
Depression1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “296.2”, “296.20”, “296.21”, “296.22”, “296.23”, “296.24”, 
“296.25”, “296.26”, “296.3”, “ 296.30”, “296.31”, “296.32”, “296.33”, “296.34”, “296.35”, “296.36”, “298.0”, 
“300.4”, “309.0”, “309.1”, “309.28”, “311” }
Diagnosis Code (Any Position), ICD -10is any of: { “F32.0”, “F32.1”, “F32.2”, “F32.3”, “F32.4”, “F32.5”, “F32.9”, 
“F33.0”, “F33.1”, “F33.2”, “F33.3”, “F33.41”, “F33.42”, “F33.9”, “F34.1”, “F43.21”, “F43.23” }
Osteoporosis 1 Inpatient or 2 Outpatient (30 – 365 days apart)
Boehringer Ingelheim Page 49of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Diagnosis Code (Any Position), ICD -9is any of: { “733.0”, “733.00”, “733.01”, “733.02”, “733.03”, “733.09”, 
“733.1”, “733.10”, “733.11”, “733.12”, “733.13”, “733.14”, “733.15”, “733.16”, “733.19” }
Diagnosis Code (Any Position), ICD -10is any of: { “M80”, “M80.0”, “M80.00”, “M80.00XA”, “M80.00XD”, 
“M80.00XG”, “M80.00XK”, “M80.00XP”, “M80.00XS”, “M80.01”, “M80.0 11”, “M80.011A”, “M80.011D”, 
“M80.011G”, “M80.011K”, “M80.011P”, “M80.011S”, “M80.012”, “M80.012A”, “M80.012D”, “M80.012G”, 
“M80.012K”, “M80.012P”, “M80.012S”, “M80.019”, “M80.019A”, “M80.019D”, “M80.019G”, “M80.019K”, 
“M80.019P”, “M80.019S”, “M80.02”, “M8 0.021”, “M80.021A”, “M80.021D”, “M80.021G”, “M80.021K”, 
“M80.021P”, “M80.021S”, “M80.022”, “M80.022A”, “M80.022D”, “M80.022G”, “M80.022K”, “M80.022P”, 
“M80.022S”, “M80.029”, “M80.029A”, “M80.029D”, “M80.029G”, “M80.029K”, “M80.029P”, “M80.029S”, 
“M80.03”, “M80.031”, “M80.031A”, “M80.031D”, “M80.031G”, “M80.031K”, “M80.031P”, “M80.031S”, 
“M80.032”, “M80.032A”, “M80.032D”, “M80.032G”, “M80.032K”, “M80.032P”, “M80.032S”, “M80.039”, 
“M80.039A”, “M80.039D”, “M80.039G”, “M80.039K”, “M80.039P”, “M80.039S”, “M80.04 ”, “M80.041”, 
“M80.041A”, “M80.041D”, “M80.041G”, “M80.041K”, “M80.041P”, “M80.041S”, “M80.042”, “M80.042A”, 
“M80.042D”, “M80.042G”, “M80.042K”, “M80.042P”, “M80.042S”, “M80.049”, “M80.049A”, “M80.049D”, 
“M80.049G”, “M80.049K”, “M80.049P”, “M80.049S”, “M80.05”, “M80.051”, “M80.051A”, “M80.051D”, 
“M80.051G”, “M80.051K”, “M80.051P”, “M80.051S”, “M80.052”, “M80.052A”, “M80.052D”, “M80.052G”, 
“M80.052K”, “M80.052P”, “M80.052S”, “M80.059”, “M80.059A”, “M80.059D”, “M80.059G”, “M80.059K”, 
“M80.059P”, “M80.059S”, “ M80.06”, “M80.061”, “M80.061A”, “M80.061D”, “M80.061G”, “M80.061K”, 
“M80.061P”, “M80.061S”, “M80.062”, “M80.062A”, “M80.062D”, “M80.062G”, “M80.062K”, “M80.062P”, 
“M80.062S”, “M80.069”, “M80.069A”, “M80.069D”, “M80.069G”, “M80.069K”, “M80.069P”, “M80.069S” , 
“M80.07”, “M80.071”, “M80.071A”, “M80.071D”, “M80.071G”, “M80.071K”, “M80.071P”, “M80.071S”, 
“M80.072”, “M80.072A”, “M80.072D”, “M80.072G”, “M80.072K”, “M80.072P”, “M80.072S”, “M80.079”, 
“M80.079A”, “M80.079D”, “M80.079G”, “M80.079K”, “M80.079P”, “M80.07 9S”, “M80.08”, “M80.08XA”, 
“M80.08XD”, “M80.08XG”, “M80.08XK”, “M80.08XP”, “M80.08XS”, “M80.8”, “M80.80”, “M80.80XA”, 
“M80.80XD”, “M80.80XG”, “M80.80XK”, “M80.80XP”, “M80.80XS”, “M80.81”, “M80.811”, “M80.811A”, 
“M80.811D”, “M80.811G”, “M80.811K”, “M80.811P ”, “M80.811S”, “M80.812”, “M80.812A”, “M80.812D”, 
“M80.812G”, “M80.812K”, “M80.812P”, “M80.812S”, “M80.819”, “M80.819A”, “M80.819D”, “M80.819G”, 
“M80.819K”, “M80.819P”, “M80.819S”, “M80.82”, “M80.821”, “M80.821A”, “M80.821D”, “M80.821G”, 
“M80.821K”, “M80.8 21P”, “M80.821S”, “M80.822”, “M80.822A”, “M80.822D”, “M80.822G”, “M80.822K”, 
Boehringer Ingelheim Page 50of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“M80.822P”, “M80.822S”, “M80.829”, “M80.829A”, “M80.829D”, “M80.829G”, “M80.829K”, “M80.829P”, 
“M80.829S”, “M80.83”, “M80.831”, “M80.831A”, “M80.831D”, “M80.831G”, “M80.831K”, “M8 0.831P”, 
“M80.831S”, “M80.832”, “M80.832A”, “M80.832D”, “M80.832G”, “M80.832K”, “M80.832P”, “M80.832S”, 
“M80.839”, “M80.839A”, “M80.839D”, “M80.839G”, “M80.839K”, “M80.839P”, “M80.839S”, “M80.84”, 
“M80.841”, “M80.841A”, “M80.841D”, “M80.841G”, “M80.841K”, “M80.841P”, “M80.841S”, “M80.842”, 
“M80.842A”, “M80.842D”, “M80.842G”, “M80.842K”, “M80.842P”, “M80.842S”, “M80.849”, “M80.849A”, 
“M80.849D”, “M80.849G”, “M80.849K”, “M80.849P”, “M80.849S”, “M80.85”, “M80.851”, “M80.851A”, 
“M80.851D”, “M80.851G”, “M80.851K”, “M80.851P”, “M80.851S”, “M80.852”, “M80.852A”, “M80.852D”, 
“M80.852G”, “M80.852K”, “M80.852P”, “M80.852S”, “M80.859”, “M80.859A”, “M80.859D”, “M80.859G”, 
“M80.859K”, “M80.859P”, “M80.859S”, “M80.86”, “M80.861”, “M80.861A”, “M80.861D”, “M80.861G”, 
“M80.8 61K”, “M80.861P”, “M80.861S”, “M80.862”, “M80.862A”, “M80.862D”, “M80.862G”, “M80.862K”, 
“M80.862P”, “M80.862S”, “M80.869”, “M80.869A”, “M80.869D”, “M80.869G”, “M80.869K”, “M80.869P”, 
“M80.869S”, “M80.87”, “M80.871”, “M80.871A”, “M80.871D”, “M80.871G”, “M8 0.871K”, “M80.871P”, 
“M80.871S”, “M80.872”, “M80.872A”, “M80.872D”, “M80.872G”, “M80.872K”, “M80.872P”, “M80.872S”, 
“M80.879”, “M80.879A”, “M80.879D”, “M80.879G”, “M80.879K”, “M80.879P”, “M80.879S”, “M80.88”, 
“M80.88XA”, “M80.88XD”, “M80.88XG”, “M80.88XK”, “M80.88XP”, “M80.88XS”, “M81”, “M81.0”, “M81.6”, 
“M81.8” }
Boehringer Ingelheim Page 51of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Charlson- Deyo 
Comorbidity IndexThis measure computes a score by summing over the following components:
· If the event Acute Myocardial Infarction Occurs within 180 days, set the score to 1.0 Oth erwise, set the score to 0.0 
· If the event Heart Failure Occurs within 180 days, set the score to 1.0 Otherwise, set the score to 0.0 
· If the event Peripheral Vascular Disease Occurs within 180 days, set the score to 1.0 Otherwise, set the score to 0.0
· If the event Cerebrovascular Disease Occurs within 180 days, set the score to 1.0 Otherwise, set the score to 0.0 
· If the event Dementia Occurs within 180 days, set the score to 1.0 Otherwise, set the score to 0.0 
· If the event Chronic Obstructive Pulmonary Disease Occurs within 180 days, set the score to 1.0 Otherwise, set the 
score to 0.0 
· If the event Rheumatologic Disease Occurs within 180 days, set the score to 1.0 Otherwise, set the score to 0.0 
· If the e vent Peptic Ulcer Disease Occurs within 180 days, set the score to 1.0 Otherwise, set the score to 0.0 
· If the event Hemiplegia or Paraplegia Occurs within 180 days, set the score to 2.0 Otherwise, set the score to 0.0 
· If the event Renal Disease Occur s within 180 days, set the score to 2.0 Otherwise, set the score to 0.0 
· If the event HIV/AIDS Occurs within 180 days, set the score to 6.0 Otherwise, set the score to 0.0 
· For the measure Cancer use the value of the measure as the score multiplied by weight 1.0 If the value is missing, set 
the score to 0.0 
· For the measure Diabetes use the value of the measure as the score multiplied by weight 1.0 If the value is missing, 
set the score to 0.0 
· For the measure Liver Disease use the value of the measure as the score multiplied by weight 1.0 If the value is 
missing, set the score to 0.0
Acute Liver Injury or 
Failure1 Inpatient or 1 Outpatient
Diagnosis Code (Any Position), ICD -9is any of: { “570”, “864.0”, “864.00”, “864.01”, “864.02”, “864.03”, 
“864.04”, “864.05”, “864.09”, “864.1”, “864.10”, “864.11”, “864.12”, “864.13”, “864.14”, “864.15”, “864.19” }
Diagnosis Code (Any Position), ICD -10is any of: { “K72.0”, “K72.00”, “K72.01”, “K72.9”, “K72.90”, “K72.91”, 
“S36.11”, “S36.112”, “S36.112A”, “S36.112D”, “S36.112S”, “S36.113”, “S36.113A”, “S36.113D”, “S36.113S”, 
“S36.114”, “S36.114A”, “S36.114D”, “S36.114S”, “S36.115”, “S36.115A”, “S36.115D”, “S36.115S”, “S36.116”, 
“S36.116A”, “S36.116D”, “S36.116S”, “S36.118”, “S36.118A”, “S36.118D”, “S36.118S ”, “S36.119”, “S36.119A”, 
“S36.119D”, “S36.119S” }
Chronic Kidney 1 Inpatient or 2 Outpatient (30 – 365 days apart)
Boehringer Ingelheim Page 52of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Disease (without 
ESRD) Diagnosis Code (Any Position), ICD -9is any of: { “585.1”, “585.2”, “585.3”, “585.4” }
Diagnosis Code (Any Position ), ICD -10is any of: { “N18.1”, “N18.2”, “N18.3”, “N18.4” }
Procedure Code (Any Position), CPT and HCPC is any of: { “G0420”, “G0421”, “G8487”, “G8771” }
End Stage Renal 
Disease1 Inpatient or 2 Outpatient (30 –365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “403.01”, “403.91”, “458.21”, “585.5”, “585.6”, “996.56”, 
“996.68”, “996.73”, “V42.0”, “V45.1”, “V45.11”, “V45.12”, “V56”, “V56.0”, “V56.1”, “V56.2”, “V56.3”, “V56.31”, 
“V56.32”, “V56.8” }
Diagnosis Code (Any Position), ICD -10is any of: { “I12.0”, “N18.5”, “N18.6”, “T86.10”, “T86.11”, “T86.12”, 
“Z49.01”, “Z49.02”, “Z49.31”, “Z49.32”, “Z91.15”, “Z94.0”, “Z99.2” }
Procedure Code (Any Position), ICD-9 is any of: { “55.69”, “55.6”, “38.95”, “39.27”, “39.42”, “39.43”, “39.95”, 
“54.98” }
Procedure Code (Any Position), ICD -10is any of: { “05HY33Z”, “06HY33Z”, “0TS00ZZ”, “0TS10ZZ”, 
“0TY00Z0”, “0TY00Z1”, “0TY00Z2”, “0TY10Z0”, “0TY10Z1”, “0TY10Z2”, “3E1M39Z”, “5A1D00Z”, 
“5A1D60Z” }
Procedure Code (Any Position), CPT and HCPC is any of: { “36145”, “36800”, “36810”, “36815”, “36825”, 
“36830”, “36831”, “36832”, “36833”, “50323”, “50325”, “50327”, “50328”, “50329”, “50340”, “50360”, “50365”, 
“90918”, “90919”, “90920”, “90921”, “90922”, “90923”, “90924”, “90925”, “90935”, “90937”, “90939”, “90940”, 
“90945”, “90947”, “90951”, “90952”, “90953”, “90954”, “90955”, “90956”, “90957”, “90958”, “90959”, “90960”, 
“90961”, “90962”, “90963”, “90964”, “90965”, “90966”, “90967”, “90968”, “90969”, “90970”, “90989”, “90993”, 
“90997”, “90999”, “93990”, “99512”, “A4653”, “A4656”, “A4657”, “A4670”, “A4671”, “A4672”, “A4673”, 
“A4674”, “A4680”, “A4706”, “A4707”, “A4708”, “A4709”, “A4712”, “A4714”, “A4719”, “A4720”, “A4721”, 
“A4722”, “A4723”, “A4724”, “A4725”, “A4726”, “A4728”, “A4730”, “A4736”, “A4737” , “A4740”, “A4750”, 
“A4755”, “A4760”, “A4765”, “A4766”, “A4770”, “A4771”, “A4773”, “A4774”, “A4802”, “A4860”, “A4870”, 
“A4890”, “A4911”, “A4913”, “A4918”, “A4928”, “A4929”, “C1881”, “E1500”, “E1520”, “E1530”, “E1540”, 
“E1550”, “E1560”, “E1570”, “E1575”, “E 1580”, “E1600”, “E1610”, “E1615”, “E1620”, “E1625”, “E1634”, 
Boehringer Ingelheim Page 53of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“E1635”, “E1636”, “E1637”, “E1639”, “E1699”, “G0257”, “G0308”, “G0309”, “G0310”, “G0311”, “G0312”, 
“G0313”, “G0314”, “G0315”, “G0316”, “G0317”, “G0318”, “G0319”, “G0320”, “G0321”, “G0323”, “G0324 ”, 
“G0325”, “G0326”, “G0327”, “G8727”, “G9013”, “G9014”, “J0635”, “J0636”, “S2065”, “S9335”, “S9339”, 
“E1638”, “G0322” }
Rheumatologic 
Disease1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “135”, “183.0”, “274.9”, “275.49”, “279.49”, “443.0”, “448.9”, 
“530.5”, “555.9”, “571.42”, “571.6”, “576.1”, “579.0”, “696.0”, “696.1”, “710.0”, “710.1”, “710.2”, “710.3”, “710.9”, 
“711.90”, “712.19”, “714.0”, “714.30”, “715.09”, “715.11”, “715.12”, “715.13”, “715.14 ”, “715.15”, “715.17”, 
“715.18”, “715.96”, “719.42”, “719.44”, “719.45”, “719.47”, “719.49”, “720.0”, “721.90”, “725”, “729.1”, “729.5”, 
“795.79” }
Diagnosis Code (Any Position), ICD -10is any of: { “D59.0”, “D59.1”, “D86.9”, “D89.89”, “E83.59”, “I73.00”,
“I73.01”, “I78.9”, “K22.4”, “K50.90”, “K74.3”, “K74.4”, “K74.5”, “K75.4”, “K83.0”, “K90.0”, “L40.0”, “L40.1”, 
“L40.2”, “L40.50”, “L40.54”, “L40.59”, “L40.8”, “M00.9”, “M06.9”, “M08.00”, “M10.9”, “M11.9”, “M15.0”, 
“M16.0”, “M16.10”, “M16.11”, “M16.12”, “M17.9”, “M19.019”, “M19.029”, “M19.039”, “M19.049”, “M19.079”, 
“M19.91”, “M25.50”, “M25.529”, “M25.559”, “M25.579”, “M32.10”, “M33.90”, “M34.0”, “M34.1”, “M34.2”, 
“M34.81”, “M34.82”, “M34.83”, “M34.89”, “M34.9”, “M35.00”, “M35.01”, “M35.02”, “M35.03”, “M35.0 4”, 
“M35.09”, “M35.3”, “M35.9”, “M45.9”, “M47.819”, “M60.9”, “M76.0”, “M76.11”, “M76.12”, “M76.8”, “M76.9”, 
“M79”, “M79.1”, “M79.609”, “M79.646” }
Boehringer Ingelheim Page 54of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Peptic Ulcer Disease1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “531”, “531.0”, “531.00”, “531.01”, “531.1”, “531.10”, “531.11”, 
“531.2”, “531.20”, “531.21”, “531.3”, “531.30”, “531.31”, “531.4”, “531.40”, “531.41”, “531.5”, “531.50”, “531.51”, 
“531.6”, “531.60”, “531.61”, “531.7”, “531.70”, “531.71”, “53 1.9”, “531.90”, “531.91”, “532”, “532.0”, “532.00”, 
“532.01”, “532.1”, “532.10”, “532.11”, “532.2”, “532.20”, “532.21”, “532.3”, “532.30”, “532.31”, “532.4”, “532.40”, 
“532.41”, “532.5”, “532.50”, “532.51”, “532.6”, “532.60”, “532.61”, “532.7”, “532.70”, “ 532.71”, “532.9”, “532.90”, 
“532.91”, “533”, “533.0”, “533.00”, “533.01”, “533.1”, “533.10”, “533.11”, “533.2”, “533.20”, “533.21”, “533.3”, 
“533.30”, “533.31”, “533.4”, “533.40”, “533.41”, “533.5”, “533.50”, “533.51”, “533.6”, “533.60”, “533.61”, “533.7”,
“533.70”, “533.71”, “533.9”, “533.90”, “533.91”, “534”, “534.0”, “534.00”, “534.01”, “534.1”, “534.10”, “534.11”, 
“534.2”, “534.20”, “534.21”, “534.3”, “534.30”, “534.31”, “534.4”, “534.40”, “534.41”, “534.5”, “534.50”, “534.51”, 
“534.6”, “534.60”, “534.6 1”, “534.7”, “534.70”, “534.71”, “534.9”, “534.90”, “534.91” }
Diagnosis Code (Any Position), ICD -10is any of: { “K25.0”, “K25.1”, “K25.2”, “K25.3”, “K25.4”, “K25.5”, 
“K25.6”, “K25.7”, “K25.9”, “K26.0”, “K26.1”, “K26.2”, “K26.3”, “K26.4”, “K26.5”, “K26.6 ”, “K26.7”, “K26.9”, 
“K27.0”, “K27.1”, “K27.2”, “K27.3”, “K27.4”, “K27.5”, “K27.6”, “K27.7”, “K27.9”, “K28.0”, “K28.1”, “K28.2”, 
“K28.3”, “K28.4”, “K28.5”, “K28.6”, “K28.7”, “K28.9” }
Gastroesophageal 
Reflux DiseaseAny of the following criteria:
≥2 medical claims with a primary or secondary ICD -9-CM code for reflux esophagitis (530.11), esophageal reflux 
(530.81) or heartburn (787.1) or primary or secondary ICD -10-CM code for GERD (K21, K21.0, K21.9) or Heartburn 
(R12) ; ≥1 medical claim with a pri mary or secondary ICD -9-CM 530.11, 530.81 or 787.1 and either (a) ≥1 pharmacy 
claim for a PPI (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole), an H2RA (cimetidine, 
famotidine, nizatidine, or ranitidine) or “other” GERD agent (bethanecho l, metoclopramide, sucralfate) or (b) ≥1 
medical claim with a primary or secondary ICD -9-CM code for esophageal stricture (530.3) Barrett’s esophagus 
(530.85), esophageal ulcer (530.2x) or esophagitis (530.1x).
Type 1 Diabetes 
Mellitus1 Inpatient or 2 Ou tpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “250.11”, “250.13”, “250.21”, “250.23”, “250.31”, “250.33”, 
“250.41”, “250.43”, “250.51”, “250.53”, “250.61”, “250.63”, “250.71”, “250.73”, “250.81”, “250.83”, “250.91”, 
Boehringer Ingelheim Page 55of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“250 .93”, “250.01”, “250.03” }
Diagnosis Code (Any Position), ICD -10is any of: { “E10”, “E10.1”, “E10.10”, “E10.11”, “E10.2”, “E10.21”, 
“E10.22”, “E10.29”, “E10.3”, “E10.31”, “E10.311”, “E10.319”, “E10.32”, “E10.321”, “E10.329”, “E10.33”, 
“E10.331”, “E10.339 ”, “E10.34”, “E10.341”, “E10.349”, “E10.35”, “E10.351”, “E10.359”, “E10.36”, “E10.39”, 
“E10.4”, “E10.40”, “E10.41”, “E10.42”, “E10.43”, “E10.44”, “E10.49”, “E10.5”, “E10.51”, “E10.52”, “E10.59”, 
“E10.6”, “E10.61”, “E10.610”, “E10.618”, “E10.62”, “E10.620”, “E10.621”, “E10.622”, “E10.628”, “E10.63”, 
“E10.630”, “E10.638”, “E10.64”, “E10.641”, “E10.649”, “E10.65”, “E10.69”, “E10.8”, “E10.9” }
Type 2 Diabetes 
Mellitus1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “250.00”, “250.02”, “250.10”, “250.12”, “250.20”, “250.22”, 
“250.30”, “250.32”, “250.40”, “250.42”, “250.50”, “250.52”, “250.60”, “250.62”, “250.70”, “250.72”, “250.80”, 
“250.82”, “250.90”, “250.92” }
Diagnosis Code (Any Position), ICD -10is any o f: { “E11.00”, “E11.01”, “E11.21”, “E11.29”, “E11.311”, 
“E11.319”, “E11.36”, “E11.39”, “E11.40”, “E11.51”, “E11.618”, “E11.620”, “E11.621”, “E11.622”, “E11.628”, 
“E11.630”, “E11.638”, “E11.641”, “E11.649”, “E11.65”, “E11.69”, “E11.8”, “E11.9”, “E13.10” }
Type 1 or Type 2 
Diabetes without 
Complications1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “250.0”, “250.00”, “250.01”, “250.02”, “250.03”, “250.1”, 
“250.10”, “250.11”, “250.12”, “250.13”, “250.2”, “250.20”, “250.21”, “250.22”, “250.23”, “250.3”, “250.7”, 
“250.70”, “250.71”, “250.72”, “250.73”, “249.0”, “249.00”, “249.01” }
Diagno sis Code (Any Position), ICD -10is any of: { “E10.1”, “E10.6”, “E10.8”, “E10.9”, “E11.0”, “E11.6”, 
“E11.8”, “E11.9”, “E13.0”, “E13.1”, “E13.6”, “E13.8”, “E13.9” }
Boehringer Ingelheim Page 56of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Type 1 or Type 2 
Diabetes with 
Complications1 Inpatient or 2 Outpatient (30 – 365 days apar t)
Diagnosis Code (Any Position), ICD -9is any of: { “250.4”, “250.40”, “250.41”, “250.42”, “250.43”, “250.5”, 
“250.50”, “250.51”, “250.52”, “250.53”, “250.6”, “250.60”, “250.61”, “250.62”, “250.63”, “250.3”, “250.30”, 
“250.31”, “250.32”, “250.33” }
Diagnosis Code (Any Position), ICD -10is any of: { “E10.2”, “E10.21”, “E10.22”, “E10.29”, “E10.3”, “E10.31”, 
“E10.311”, “E10.319”, “E10.32”, “E10.321”, “E10.329”, “E10.33”, “E10.331”, “E10.339”, “E10.34”, “E10.341”, 
“E10.349”, “E10.35”, “E10.351”, “E10.359”, “E10.36”, “E10.39”, “E10.4”, “E10.40”, “E10.41”, “E10.42”, 
“E10.43”, “E10.44”, “E10.49”, “E10.5”, “E11.2”, “E11.21”, “E11.22”, “E11.29”, “E11.3”, “E11.31”, “E11.311”, 
“E11.319”, “E11.32”, “E11.321”, “E11.329”, “E11.33”, “E11.331”, “E11.339”, “E11.34”, “E11. 341”, “E11.349”, 
“E11.35”, “E11.351”, “E11.359”, “E11.36”, “E11.39”, “E11.4”, “E11.40”, “E11.41”, “E11.42”, “E11.43”, “E11.44”, 
“E11.49”, “E11.5”, “E13.4”, “E13.40”, “E13.41”, “E13.42”, “E13.43”, “E13.44”, “E13.49”, “E13.5” }
Mild Liver Disease1 Inpatien t or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “571.2”, “571.4”, “571.40”, “571.41”, “571.42”, “571.49”, 
“571.5”, “571.6” }
Diagnosis Code (Any Position), ICD -10is any of: { “B18.0”, “B18.1”, “B18.2”, “B18.8”, “B18.9”, “K70.0”, 
“K70.1”, “K70.10”, “K70.11”, “K70.2”, “K70.3”, “K70.9”, “K71.3”, “K71.4”, “K71.5”, “K71.7”, “K73.0”, “K73.1”, 
“K73.2”, “K73.8”, “K73.9”, “K74.0”, “K74.1”, “K74.2”, “K74.3”, “K74.4”, “K74.5”, “K74.6”, “K74.60”, “K74.69”, 
“K76.0”, “K76.2”, “K76.3”, “K76.4”, “K76.8”, “K76.9”, “Z94.4” }
Moderate/Severe 
Liver Disease1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “456.0”, “456.1”, “456.2”, “456.20”, “456.21”, “572.2”, 
“572.3”, “572.4”, “572.8” }
Diagnosis Code (Any Position), ICD -10is any of: { “I85.0”, “I86.4”, “K70.4”, “K71.1”, “K72.1”, “K72.9”, 
“K76.5”, “K76.6”, “K76.7” }
Boehringer Ingelheim Page 57of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Renal Disease1 Inpatie nt or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “582”, “582.0”, “582.1”, “582.2”, “582.4”, “582.8”, “582.81”, 
“582.89”, “582.9”, “583”, “583.0”, “583.1”, “583.2”, “583.4”, “583.6”, “583.7”, “585”, “585.1”, “585.2 ”, “585.3”, 
“585.4”, “585.5”, “585.6”, “585.9”, “586”, “588”, “588.0”, “588.1”, “588.8”, “588.81”, “588.89”, “588.9” }
Diagnosis Code (Any Position), ICD -10is any of: { “I12.0”, “I13.1”, “N03.2”, “N03.3”, “N03.4”, “N03.5”, 
“N03.6”, “N03.7”, “N05.2”, “N05.3”, “N05.4”, “N05.5”, “N05.6”, “N05.7”, “N18.1”, “N18.2”, “N18.3”, “N18.4”, 
“N18.5”, “N18.6”, “N18.9”, “N25.0”, “Z49.0”, “Z49.01”, “Z49.02”, “Z94.0”, “Z99.2” }
Metastatic Solid 
Tumors1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “196”, “196.0”, “196.1”, “196.2”, “196.3”, “196.5”, “196.6”, 
“196.8”, “196.9”, “197”, “197.0”, “197.1”, “197.2”, “197.3”, “197.4”, “197.5”, “197.6”, “197.7”, “197.8”, “198”, 
“198.0”, “198.1”, “198.2”, “198.3”, “198.4”, “198.5 ”, “198.6”, “198.7”, “198.8”, “198.81”, “198.82”, “198.89”, 
“199”, “199.0”, “199.1” }
Diagnosis Code (Any Position), ICD -10is any of: { “C77.0”, “C77.1”, “C77.2”, “C77.3”, “C77.4”, “C77.5”, 
“C77.8”, “C77.9”, “C78”, “C78.0”, “C78.00”, “C78.01”, “C78.02”, “C78.1”, “C78.2”, “C78.3”, “C78.30”, “C78.39”, 
“C78.4”, “C78.5”, “C78.6”, “C78.7”, “C78.8”, “C78.80”, “C78.89”, “C79”, “C79.0”, “C79.00”, “C79.01”, “C79.02”, 
“C79.1”, “C79.10”, “C79.11”, “C79.19”, “C79.2”, “C79.3”, “C79.31”, “C79.32”, “C79.4”, “C79.40”, “C 79.49”, 
“C79.5”, “C79.51”, “C79.52”, “C79.6”, “C79.60”, “C79.61”, “C79.62”, “C79.7”, “C79.70”, “C79.71”, “C79.72”, 
“C79.8”, “C79.81”, “C79.82”, “C79.89”, “C79.9”, “C80”, “C80.0”, “C80.1”, “C80.2” }
HIV/AIDS1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “042”, “795.71”, “V08”, “V65.44”, “079.53” }
Diagnosis Code (Any Position), ICD -10is any of: { “B20”, “Z21”, “B97.35”, “O98.7*”, “Z71.7” }
Hemiplegia or 
Paraplegia1 Inpatient or 2 Outpatient (30 – 365 days apart)
Diagnosis Code (Any Position), ICD -9is any of: { “342”, “342.0”, “342.00”, “342.01”, “342.02”, “342.1”, “342.10”, 
Boehringer Ingelheim Page 58of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015“342.11”, “342.12”, “342.8”, “342.80”, “342.81”, “342.82”, “342.9”, “342.90”, “342.91”, “342.92”, “344.1” }
Diagnosis Cod e (Any Position), ICD -10is any of: { “G81.00”, “G81.01”, “G81.02”, “G81.03”, “G81.04”, “G81.10”, 
“G81.11”, “G81.12”, “G81.13”, “G81.14”, “G81.90”, “G81.91”, “G81.92”, “G81.93”, “G81.94”, “G82.20”, “G81”, 
“G81.9”, “I69.05”, “I69.051”, “I69.052”, “I69.053”, “I69.054”, “I69.059”, “I69.15”, “I69.151”, “I69.152”, “I69.153”, 
“I69.154”, “I69.159”, “I69.25”, “I69.251”, “I69.252”, “I69.253”, “I69.254”, “I69.259”, “I69.35”, “I69.351”, 
“I69.352”, “I69.353”, “I69.354”, “I69.359”, “I69.85”, “I69.851”, “I69.852”, “I69.8 53”, “I69.854”, “I69.859”, 
“I69.95”, “I69.951”, “I69.952”, “I69.953”, “I69.954”, “I69.959”, “G81.0”, “G81.1”, “G82.2”, “G82”, “G82.21”, 
“G82.22”, “G04.1”, “G11.4” }
Lifestyle
Smoking -related 
claim1 Inpatient or 1 Outpatient
Diagnosis Code (Any Position), ICD -9is any of: { “305.1”, “V15.82, “989.84”, “649.0x” }
Diagnosis Code (Any Position), ICD -10is any of: { “F17.2”, “T65.2”, “Z71.6”, “O99.33”, “O99.330”, “O99.331”, 
“O99.332”, “O99.333”, “O99.334”, “O99.335”, “Z72.0”, “Z81.2” }
Procedure Code (Any Position), CPT and HCPC is any of: { “99406”, “99407”, “G0436”, “G0437”, “G9016”, 
“S9453”, “S4995”, “G9276”, “G9458”, “1034F”, “4004F”, “4001F”}
Vaccination for 
Influenza/Pneumococ
cus1 Inpatient Service or 1 Outpatient
Procedure Code (Position 1), CPT and HCPC is any of: { “4040F”, “90630”, “90653”, “90654”, “90655”, “90656”, 
“90657”, “90658”, “90659”, “90660”, “90661”, “90662”, “90663”, “90664”, “90665”, “90666”, “90667”, “90668”, 
“90669”, “90670”, “90672”, “90673”, “90685”, “90686”, “90687”, “ 90688”, “90732”, “G0008”, “G0009”, “G0919”, 
“G8108”, “G8115”, “G8864”, “G9279”, “Q0034”, “Q2033”, “Q2034”, “Q2035”, “Q2036”, “Q2037”, “Q2038”, 
“Q2039”, “S0195” }
Boehringer Ingelheim Page 59of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Respiratory Function Procedures/Tests
Pulmonary function 
tests1 Inpatient or 1 Outpatient
Procedure Code (Any Position), CPT and HCPC is any of: { “3038F”, “94010”, “94014”, “94015”, “94060”, 
“94621”, “94720”, “94725”, “94726”, “94727”, “94728”, “94729”, “94750”, “94770”, “94799” }
Procedure Code (Any Position), ICD -9is any of: { “89.37” }
Procedure Code (Any Position), ICD -10is any of: { “4A0971Z”, “4A0981Z”, “4A09X1Z”, “4A1971Z”, 
“4A19X1Z” }
Six-minute walk test1 Inpatient or 1 Outpatient
Legacy Attribute - Procedure Code (Any Position) is any of: { “94620” }
Chest X -ray1 Inpatient or 1 Outpatient
Procedure Code (Any Position), CPT and HCPC is any of: { “71010”, “71020”, “71021”, “71022”, “71023”, 
“71030”, “71034”, “71035” }
High Resolution 
Chest CT1 Inpatient or 1 Outpatient
Procedure Code (Any Position), CPT and HCPC is any of: { “71250”, “71270” }
Boehringer Ingelheim Page 60of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015ANNEX 5. TABLE SHELL S AND PROPOSED FIGUR ES
Table 1. Cohort Selection 
Excluded Remaining
Eligible Population
Did not meet cohort entry criteria (use of Tio/Olo or Umec/Vi )
< 180 days of continuous enrollment
Prior use of Umec/Vi during 180d washout
Prior use of Tio/Olo during 180d washout
Tio/Olo and Umec/Vi both occurring on cohort entry date
Age <40 years
No prior diagnosis of COPD any time prior using all available data
Diagnosis of Asthma any time prior using all available data
Diagnosis of Lung Cancer any time prior using all available data
Lung Transplant any time prior using all available data
Final cohort
Boehringer Ingelheim Page 61of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Table 2. Patient Characteristics of the Study  Population (Unmatched / Matched )
Tio/Olo Umec/Vi Standardized Difference (95% CI)
N
Median Follow -up Time [IQR]
Demographics
Age on index date
Mean (SD)
Median [IQR]
Gender
Male; n (%)
Female; n (%)
Region
Northeast; n (%)
North Central; n (%)
South; n (%)
West; n (%)
Missing/Unknown; n (%)
Insurance Type
Commercial; n (%)
Medicare; n (%)
Missing; n (%)
Year of Cohort Entry, n (%)
First Year (November 17,2015 –November 30, 2016); n (%)
Second Year (December 1, 2016 – November 30, 2017 ); n (%)
Third Year (December 1, 2017 to March 31, 2018)
Concomitant Medications
Boehringer Ingelheim Page 62of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Tio/Olo Umec/Vi Standardized Difference (95% CI)
Oral Corticosteroids; n (%)
Short acting muscarinic antagonist (SAMA), n (%)
Short acting beta agonist (SABA), n (%)
Long acting muscarinic antagonist (LAMA), n (%)
Long acting beta agonist (LABA), n (%)
Inhaled corticosteroid (ICS), n (%)
LAMA / LABA combination (not Tio/Olo or Umec/Vi), n (%)
LABA / ICS combination, n (%)
LAMA / LABA / ICS combination, n (%)
NSAIDs, n (%)
Antihistamines, n (%)
Opioids, n (%)
Oral antibiotics, n (%)
Antidiabetic Agents (not including insulin), n (%)
Insulin (basal or mealtime), n (%)
Methotrexate, n (%)
Statins; n (%)
Antihypertensives; n (%)
Anticoagulants; n (%)
Anti- psychotic/anti -depressives/anxiolytic, n (%)
Oxygen therapy, n (%)
Comorbidities /Symptoms
History of All -Cause Hospitalization; n (%)
History of Emergency Department Visit; n (%)
History of Hospitalization due to Respiratory Condition; n (%)
Acute Myocardial Infarction; n (%)
Angina Pectoris; n (%)
Peripheral Vascular Disease; n (%)
Boehringer Ingelheim Page 63of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Tio/Olo Umec/Vi Standardized Difference (95% CI)
Heart Failure; n (%)
Hypertension; n (%)
Upper Respiratory Tract Infection; n (%)
Lower Respiratory Tract Infection; n (%)
Cardiac Arrhythmias; n (%)
Cerebrovascular Disease; n (%)
All Cancers (except non- melanoma skin cancer); n (%)
Allergic Rhinitis; n (%)
Chronic Sinusitis; n (%)
Bronchietasis; n (%)
Pneumonia; n (%)
Chronic Bronchitis; n (%)
Exertional Breathlessness; n (%)
Anxiety; n (%)
Dementia; n (%)
Depression; n (%)
Osteoporosis; n (%)
Charlson -Deyo Comorbidity Index, continuous
mean (sd)
median [IQR]
Charlson -Deyo Comorbidity Index, categorical
0; n (%)
1; n (%)
2; n (%)
3+; n (%)
Acute Liver Injury or Failure; n (%)
Chronic Kidney Disease (without ESRD); n (%)
End Stage Renal Disease; n (%)
Rheumatologic Disease; n (%)
Boehringer Ingelheim Page 64of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Tio/Olo Umec/Vi Standardized Difference (95% CI)
Peptic Ulcer Disease; n (%)
Gastroesophageal reflux disease (GERD); n (%)
Type 1 Diabetes Mellitus; n (%)
Type 2 Diabetes Mellitus; n (%)
Type 1 or Type 2 Diabetes with no chronic complications; n (%)
Type 1 or Type 2 Diabetes with chronic complications; n (%)
Mild Liver Disease; n (%)
Moderate to Severe Liver Disease; n (%)
Renal Disease; n (%)
Metastatic Solid Tumor; n (%)
HIV/AIDS; n (%)
Hemiplegia or Paraplegia; n (%)
Lifestyle
Smoking Related Claim or Intervention; n (%)
Vaccination for Influenza; n (%)
Vaccination for Pneumococcus; n (%)
Respiratory Function Procedures/Tests
Pulmonary function tests; n (%)
Six-minute walk test; n (%)
Chest X -ray; n (%)
Chest HRCT; n (%)
Tio/Olo, tiotropium/olodaterol; Umec/Vi, umeclidinium, vilanterol.
Boehringer Ingelheim Page 65of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Table 3 .Absolute Standardized Differences as Measured in the Unmatched vs. Matched Cohorts
Abs. Std. Diff. 
(Unmatched)Abs. Std. Diff. 
(Matched)Change Change (%)
Demographics
Age on index date
Gender
Region
Insurance Type
Year of Cohort Entry
Oral Corticosteroids; n (%)
Short acting muscarinic antagonist (SAMA), n (%)
Short acting beta agonist (SABA), n (%)
Long acting muscarinic antagonist (LAMA), n (%)
Long acting beta agonist (LABA), n (%)
Inhaled corticosteroid (ICS), n (%)
LAMA / LABA combination (not Tio/Olo or 
Umec/Vi), n (%)
LABA / ICS combination, n (%)
LAMA / LABA / ICS combination, n (%)
NSAIDs, n (%)
Antihistamines, n (%)
Opioids, n (%)
Oral antibiotics, n (%)
Antidiabetic Agents (not including insulin), n (%)
Insulin (basal or mealtime), n (%)
Methotrexate, n (%)
Statins; n (%)
Antihypertensives; n (%)
Anticoagulants; n (%)
Boehringer Ingelheim Page 66of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Abs. Std. Diff. 
(Unmatched)Abs. Std. Diff. 
(Matched)Change Change (%)
Anti- psychotic/anti -depressives/anxiolytic, n (%)
Oxygen therapy, n (%)
Comorbidities /Symptoms
History of All -Cause Hospitalization; n (%)
History of Emergency Department Visit; n (%)
History of Hospitalization due to Respiratory 
Condition; n (%)
Acute Myocardial Infarction; n (%)
Angina Pectoris; n (%)
Peripheral Vascular Disease; n (%)
Heart Failure; n (%)
Hypertension; n (%)
Upper Respiratory Tract Infection; n (%)
Lower Respiratory Tract Infection; n (%)
Cardiac Arrhythmias; n (%)
Cerebrovascular Disease; n (%)
All Cancers (except non- melanoma skin cancer); n 
(%)
Allergic Rhinitis; n (%)
Chronic Sinusitis; n (%)
Bronchietasis; n (%)
Pneumonia; n (%)
Chronic Bronchitis; n (%)
Exertional Breathlessness; n (%)
Anxiety; n (%)
Dementia; n (%)
Depression; n (%)
Osteoporosis; n (%)
Boehringer Ingelheim Page 67of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Abs. Std. Diff. 
(Unmatched)Abs. Std. Diff. 
(Matched)Change Change (%)
Charlson -Deyo Comorbidity Index, continuous
Charlson -Deyo Comorbidity Index, categorical
Acute Liver Injury or Failure; n (%)
Chronic Kidney Disease (without ESRD); n (%)
End Stage Renal Disease; n (%)
Rheumatologic Disease; n (%)
Peptic Ulcer Disease; n (%)
Gastroesophageal reflux disease (GERD); n (%)
Type 1 Diabetes Mellitus; n (%)
Type 2 Diabetes Mellitus; n (%)
Type 1 or Type 2 Diabetes with no chronic 
complications; n (%)
Type 1 or Type 2 Diabetes with chronic 
complications; n (%)
Mild Liver Disease; n (%)
Moderate to Severe Liver Disease; n (%)
Renal Disease; n (%)
Metastatic Solid Tumor; n (%)
HIV/AIDS; n (%)
Hemiplegia or Paraplegia; n (%)
Vaccination for Influenza / Pneumococcus; n (%)
Respiratory Function Procedures/Tests
Pulmonary function tests; n (%)
Six-minute walk test; n (%)
Chest X -ray; n (%)
Chest HRCT; n (%)
Tio/Olo, tiotropium/olodaterol; Umec/Vi, umeclidinium, vilanterol.
Boehringer Ingelheim Page 68of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Table 4 . Unmatched Cohort Discontinuation Rates and Risks for Tio/Olo vs. Umec/Vi.
Parameter Tio/Olo Umec/Vi
Number of patients
Number of person -years
Number of events (discontinuations)
Rate
Rate per 1,000 person -years
Rate Difference per 1,000 person -years (95% CI) 1.0 (Reference)
Rate Ratio (95% CI) 1.0 (Reference)
Risk
Risk per 1,000 patients
Risk Difference per 1,000 person -years (95% CI) 1.0 (Reference)
Risk Ratio (95% CI) 1.0 (Reference)
Primary Estimates
Unadjusted Hazard Ratio (95% CI) 1.0 (Reference)
Fully adjusted Hazard Ratio (95% CI) 1.0 (Reference)
Tio/Olo, tiotropium/olodaterol; Umec/Vi, umeclidinium, vilanterol.
Boehringer Ingelheim Page 69of 69
Protocol for non -interventional studies based on existing data
BI Study Number 1237 -0090 c30445781-01
Proprietary confidential information © 201 9Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCG-102_RD -02(1.0) /Saved on:22Oct2015Table 5 . 1:2 Matched Cohort Discontinuation Risk for Tio/Olo vs. Umec/Vi.
Parameter Tio/Olo Umec/Vi
Number of patients
Number of person -years
Number of events (discontinuations)
Rate
Rate per 1,000 person -years
Rate Difference per 1,000 person- years (95% CI) 1.0 (Reference)
Rate Ratio (95% CI) 1.0(Reference)
Risk
Risk per 1,000 patients
Risk Difference per 1,000 person -years (95% CI) 1.0 (Reference)
Risk Ratio (95% CI) 1.0 (Reference)
Primary Estimates
Matched Hazard Ratio (95% CI) 1.0 (Reference)
Tio/Olo, tiotropium/ olodaterol; Umec/Vi, umeclidinium, vilanterol.
   
 
APPROVAL / SIGNATURE PAGE 
 Document Number:  Technical Version Number:  
Document Name:  
  
                                                                                                                  
Title:  
 
 
 
                                                                                                                    
Signatures (obtained electronically) 
 
Meaning of Signature  Signed by Date Signed 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
   
 
  
  
   
 
  
  
  
 
 
  
  
 c30445781 1.0
clinical-trial-protocol
The Role of Inhaler Device in the Treatment Persistence with Dual Bronchodilators
in Patients with COPD
Approval-  Safety Evaluation
Therapeutic Area22 Nov 2019 12:25 CET
Author-Other 25 Nov 2019 08:53 CET
Approval-  of GlobalEpidemiology08 Dec 2019 17:18 CET
Approval-Team Member Medicine 09 Dec 2019 12:07 CET
Approval-Team Member Medicine 12 Dec 2019 12:29 CET

Boehringer Ingelheim Page  2 of 2
Document Number:  Technical Version Number :  
 
 (Continued) Signatures (obtained electronically) 
 
Meaning of Signature  Signed by Date Signed 
 
   
  
 
 
  
  
  
 
  
 
    
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 c30445781 1.0